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cists, Austrian Society for Infectious Diseases and Tropical 
Medicine, Austrian Society for Antimicrobial Chemother-
apy, Robert Koch Institute.
Materials and methods A structured literature research 
was performed in the databases EMBASE, BIOSIS, MED-
LINE and The Cochrane Library from January 2006 to 
November 2010 with an update to April 2012 (MEDLINE 
and The Cochrane Library). The grading of recommenda-
tions in relation to their evidence is according to the AWMF 
Guidance Manual and Rules for Guideline Development.
Conclusion The guideline provides the grounds for 
rational use of antibiotics in hospital to counteract anti-
microbial resistance and to improve the quality of care of 
patients with infections by maximising clinical outcomes 
while minimising toxicity. Requirements for a success-
ful implementation of ABS programmes as well as core 
and supplemental ABS strategies are outlined. The Ger-
man version of the guideline was published by the German 
Association of the Scientific Medical Societies (AWMF) in 
December 2013.
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Abstract 
Introduction In the time of increasing resistance and pau-
city of new drug development there is a growing need for 
strategies to enhance rational use of antibiotics in German 
and Austrian hospitals. An evidence-based guideline on 
recommendations for implementation of antibiotic stew-
ardship (ABS) programmes was developed by the Ger-
man Society for Infectious Diseases in association with 
the following societies, associations and institutions: Ger-
man Society of Hospital Pharmacists, German Society for 
AWMF (Association of the Scientific Medical Societies in 
Germany) Registry No. 092/001.
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I  Introduction and aims of the guideline
The dramatic increase in antibiotic resistance seen in many 
areas and regions combined with the paucity of new drug 
development more than ever calls for prudent, controlled, and 
appropriate use of antiinfectives in all areas of medicine. This 
affects almost all disciplines and medical specialties. The den-
sity of antiinfective treatment—with all its implications for 
cost, toxicity, the emergence of resistance and recommenda-
tions on diagnosis and follow-up, as well as recommendations 
on further therapy in the outpatient setting—is so high, in par-
ticular in the hospital sector, that safety and quality assurance 
processes will no longer succeed without a panel of experts 
and strategic discussions. Following a first position paper 
of the European Commission in 2001, in a second report on 
“Prudent use of antimicrobial agents in human medicine” 
published in 2010, EU Member States were recommended to 
establish or enhance surveillance systems for antibiotic resist-
ance and antibiotic consumption. Particular importance gains 
this recommendation in Germany in light of the amendment 
of the Infection Protection Act [Infektionsschutzgesetz (IfSG), 
especially §4 and §23] in July 2011. The Act not only stipu-
lates collection of data on antibiotic consumption, pathogenic 
microorganisms and resistance, it also requires that data on 
antibiotic consumption be assessed taking into account the 
local resistance situation, and that appropriate conclusions be 
drawn regarding the use of antibiotics. Furthermore, that the 
necessary adjustments to antibiotic consumption be commu-
nicated to staff and implemented (IfSG § 23 paragraph 4). 
Antibiotic stewardship (ABS) programmes should and can 
assume this responsibility in combination with policies and 
programmes for infection prevention. The aim of ABS pro-
grammes in hospital is to continuously improve the quality of 
antiinfective prescribing with regard to agent selection, dosing, 
administration and duration of treatment in order to maximise 
clinical outcomes while minimising toxicity to the patient as 
well as the emergence of resistance and costs.
Many reviews published since 2005 [1–12] on antibiotic 
stewardship describe the requirements and elements needed 
to institutionalise this type of programme in hospitals. More 
recent publications also detail use of these programmes in 
intensive care units [13–15], paediatrics [16–18] or small 
community hospitals [19–21]. A relatively new systematic 
review on ABS activities in critical care medicine, assesses 
24 studies between 1996 and 2010, among them six meth-
odologically ambitious investigations [15]. These were pro-
jects limiting cephalosporin use to minimise the emergence 
of resistance, studies on the implementation of computerised 
decision support systems and infectious diseases consultation 
services, as well as introduction of new guidelines for therapy 
and prophylaxis. The review provides good insight into the 
effects of various ABS strategies on consumption, costs and 
resistance, as demonstrated in recent years by a number of 
other original papers. Most studies show a 10–40 % reduc-
tion in antiinfective drug use, shorter treatment duration 
and cost reduction. Programmes that were active for longer 
than 6 months were also associated with an improvement in 
resistance rates depending on the drug–pathogen combina-
tion [15]. A recent Cochrane review of 2013 (89 studies up 
to 2007) reached a similar conclusion. The review shows 
that the effect of interventions (e.g. antimicrobial restriction) 
is usually delayed (6 months) in respect of microbiologi-
cal endpoints (e.g. antibiotic resistance); however, a prompt 
effect (frequently as soon as 1 month) is noted with regard 
to prescribing endpoints. According to the meta-analysis of 
methodologically robust studies (including randomised and 
controlled before-after studies with interrupted time-series 
analyses), professional interventions to reduce excessive anti-
infective prescribing are successful in minimising the emer-
gence of resistance and reducing hospital-acquired infections, 
as well as in improving individual treatment outcomes [22].
The two most recent reviews mentioned demonstrate the 
importance of ABS programmes and rational prescribing 
strategies in terms of minimising resistance. Instituting ABS 
programmes to save costs is not any more the driving factor, 
although this aspect is still important. An analysis published 
in 2012 on the cost-effectiveness of an ABS programme ini-
tiated at a University Hospital in Maryland, USA, showed 
interesting results. Over a period of 3 years, gross sav-
ings of roughly USD 3 million were realised, i.e. approxi-
mately USD 1 million/year. This was opposed by expenses 
of roughly USD 200,000/year to finance the programme 
(personnel costs). Although yearly cost savings dropped to 
approximately USD 400,000 p.a. over the full 7-year term 
of the ABS programme, it nevertheless remained cost-effec-
tive and delivered net savings with only one full-time per-
sonnel per 500 beds (infectious diseases physician, pharma-
cist, IT specialist). When the programme was discontinued 
after 7 years, antiinfective costs rapidly rose by around USD 
2 million during the subsequent 2 years [23]. Cost–ben-
efit analyses performed in other more recent pharmacoeco-
nomic investigations of ABS programmes are no longer lim-
ited to the potential “savings” achieved in drug and material 
costs; rather they show that adequate antiinfective therapy 
is associated with lower mortality, shorter length of hospi-
tal stay and duration of treatment, and that it can reduce the 
overall cost of treatment and improve patient safety [24].
This guideline recommends and outlines the require-
ments and main elements of ABS programmes with which 
the above objectives can be achieved. The recommenda-
tions are based on a systematic evaluation of many new 
observational and interventional studies with clinical and 
microbiological endpoints, as well as the endpoints antiin-
fective prescribing and costs, which were mainly conducted 
in adult patients in acute-care hospitals. The available litera-
ture was compiled based on the guideline published by two 
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American societies (IDSA, SHEA) focusing on the devel-
opment of facility-specific ABS programmes (“Guidelines 
for Developing an Institutional Program to Enhance Antimi-
crobial Stewardship”) as well as on a Cochrane Review by 
Davey et al. from 2005 on “Interventions to improve antibi-
otic prescribing practices for hospital inpatients (Review)”, 
taking into account its update (2013) [2, 6, 22, 25]. Further 
literature was systematically searched until 15 April 2012 
and evaluated. For details see the methodology report pub-
lished online (http://www.awmf.org). Although some of the 
recommendations are not new in content, they altogether 
draw on much better study evidence and a greater number 
of examples for successful programmes. The recommenda-
tions were derived by consensus by the guideline develop-
ment group based on review of the literature, taking into 
account relevance, evidence, applicability and practicabil-
ity in German and Austrian acute-care hospitals. Key chal-
lenges are the current trends in multidrug-resistant patho-
gens (VRE, multidrug-resistant Gram-negative bacteria) 
and Clostridium difficile in Germany and Austria, the lack 
of skilled personnel—especially infectious diseases physi-
cians—and limited experience with well-functioning infec-
tious disease consultation services established elsewhere, 
increasing cost pressure in hospitals and outsourcing of 
microbiological diagnostics.
For the purpose of safety and quality assurance, it is rec-
ommended to use a selection of indicators from a catalogue 
developed and agreed upon by members of the guideline 
development group and users in Germany. Further experi-
ence with validation especially of process indicators as well 
as international experience gained in particularly France, 
England and Scotland on use of such indicators for internal 
and external quality assurance should be taken into account.
II  Summary of recommendations
1  Requirements
1.1  Availability of a team of ABS experts
For effective implementation of ABS programmes, it is 
essential that a multidisciplinary team should be instructed 
by the hospital administration and allocated with adequate 
resources to draw up guidelines derived by consensus with 
the users for the treatment of infectious diseases and to 
ensure their implementation through ABS strategies (A).
The team should consist of at least one infectious diseases 
physician (or clinician with infectious diseases training) and 
an experienced clinical pharmacist/hospital pharmacist, as 
well as a specialist in microbiology, virology and infection 
epidemiology being responsible for laboratory diagnostic 
and microbiological consultation; furthermore, the physician 
locally responsible for infection control. The team members 
should either have appropriate training in antibiotic steward-
ship or already be sufficiently experienced (A).
The team will receive the support and collaboration of 
the hospital administration, and activities within the ABS 
programme should be compensated with a minimum of one 
full-time equivalent (FTE) of 0.5 per 250 beds (A). There 
should be good collaboration between the Therapeutics and 
Drugs Committee, Hospital Infection Control Committee, 
pharmacy and representatives of clinical divisions/depart-
ments (ABS representatives), for which purpose the team 
should issue its own Rules of Procedure (A).
Significance in practice:
•	 ABS programmes should be instituted facility-wide 
which necessitates a multidisciplinary team with the 
competence for interdisciplinary cooperation.
•	 Infectious diseases specialists serving as consultants 
improve the clinical outcome of patients with infections, 
and ensure the quality of drug prescribing.
•	 Clinical pharmacists improve the quality of drug pre-
scribing (e.g. dosing and drug application, avoidance of 
adverse drug events).
•	 Microbiologists facilitate high-grade infection medicine 
by ensuring the quality of microbiological diagnostics 
and preanalytics, and by expertly evaluating and con-
veying microbial culture results.
•	 Various ABS programmes describe an FTE of 0.5 per 
250 beds as being the minimum staff resources neces-
sary to cost-effectively conduct an ABS programme.
1.2  Availability of surveillance data on pathogens, 
resistance, and antimicrobial consumption
1.2.1 Pathogens and resistance Antimicrobial susceptibil-
ity data on major pathogens should be available and accessi-
ble at least yearly on a hospital-wide level and separately for 
general and intensive care units, or department-specific, as 
the case may be. Data on primary isolates should be shown 
by pathogen and type of specimen, e.g. blood, urine, miscel-
laneous samples. Culture results from screening tests should 
be shown separately. Susceptibility rates should indicate the 
number of isolates tested. Infection rates should relate con-
sistently to a single denominator (e.g. patient-days/number 
of cases). Participation in an established surveillance system 
is recommended (A).
Significance in practice:
•	 Conducting an additional material analysis (e.g. number 
of blood culture sets per patient or 1000 patient-days, 
number of urine cultures per patient, number of cath-
eter-associated urine cultures, etc.) also with regard to 
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material quality and positivity/contamination rates (e.g. 
blood cultures) can be useful.
•	 Whether the susceptibility rates of pathogens should be 
limited to agents listed on the hospital formulary should 
be discussed within the team.
•	 The amendment of the Infection Protection Act 
(Infektionsschutzgesetz, IfSG) (reporting, documenta-
tion) is mandatory.
1.2.2 Antimicrobial consumption Data on antimicro-
bial consumption, expressed as use density (daily doses 
per 100 patient-days) should be collected at least annu-
ally or preferably quarterly and are generally reported by 
the pharmacist. Data are reported institution-wide, at the 
ward level as well as for individual (speciality) depart-
ments. On demand, data should be broken down to the 
agent level and should be provided to the ABS team. Par-
ticipation in an established surveillance system is recom-
mended (A).
Point prevalence surveys should be conducted for sys-
tematic quantitative and qualitative assessment of antiinfec-
tive use, and, if required should be reevaluated short-term 
(A). Antiinfective use data are collected at the patient level 
which allows to assess prescribing quality based on indi-
cation and type of infection, and to recognise the need for 
targeted ABS strategies. Access to patient-level data ought 
to be guaranteed.
Significance in practice:
•	 Use density should be presented by antibiotic class and 
not only by individual agent.
•	 Reporting consumption data and antiinfective costs 
ranked by individual agent or class (e.g. top 5 or 10) is 
also reasonable.
•	 Point prevalence surveys are a simple tool to examine 
process quality.
•	 The amendment of the Infection Protection Act 
(Infektionsschutzgesetz, IfSG) (reporting, documenta-
tion) must be observed.
2  ABS core strategies
2.1  Application of local treatment guidelines/pathways, 
hospital antiinfective formulary, formulary restrictions 
and approval requirements
Developing and updating local treatment guidelines, clini-
cal pathways, and an antiinfective formulary is one of 
the ABS team’s chief responsibilities. The antiinfective 
formulary should be based on national and international 
guidelines as well as on the local/regional pathogen and 
resistance patterns, and possibly drug costs. Drugs on the 
antiinfective formulary should be categorised according 
to recommended versus reserve or special compounds. 
In addition, these should be tagged with special prescrip-
tion status and be subject to approval and preauthorisa-
tion requirements. The antiinfective formulary is updated 
at least yearly based on therapy guidelines and whenever 
necessary and approved by the Therapeutics and Drugs 
Committee (A).
Adherence to guidelines regarding substance selec-
tion, dosing, route and duration of treatment may improve 
clinical outcome in terms of mortality, as well as treatment 
duration and length of hospital stay. To ensure adherence, 
users should be involved in developing the guidelines and 
be educated through audits of antiinfective use or antiinfec-
tive point-of-care chart reviews (A).
Individualising antiinfective prescriptions with or with-
out special approval requirements improves targeted ther-
apy and reduces inappropriate treatment. Various possibili-
ties for implementation have been described and should be 
used, from simple antimicrobial order forms to highly dif-
ferentiated antiinfective request forms that may be subject 
to specific time limits or limited to certain hospital areas 
(A). Guideline-based antiinfective drug use or use of indi-
vidual defined substances can be controlled by this means, 
thus minimising consumption, costs and adverse drug 
events.
Restricting whole substance classes can—by shifting 
to an alternative substance—prove to be an effective strat-
egy for controlling nosocomial infections and the develop-
ment of critical resistance levels; accordingly, antiinfec-
tive restriction ought to be targeted (B). At the same time, 
routine surveillance of antibiotic consumption and locally 
prevalent pathogens and their susceptibility patterns should 
be performed to detect possible adverse effects of the strat-
egy in time (A).
Significance in practice:
•	 Local guidelines serve quality assurance and are a core 
strategy of every ABS programme.
•	 The antiinfective formulary is a useful ABS tool espe-
cially in small and medium-sized hospitals.
•	 Clinical pathways are rarely employed, can, however, 
be very helpful in the emergency room.
•	 Special order forms are highly effective ABS tools. 
Efforts should be undertaken to foster acceptance by 
prescribers.
•	 Restrictions on use to control resistance and nosocomial 
infections are frequently only temporarily effective. 
They should be time-restricted by the ABS team and 
reconsidered depending on the effects.
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2.2  Design and implementation of education, training 
and information
Targeted education, training and information are essen-
tial elements of any ABS programme. They provide 
the foundation of knowledge needed to promote more 
rational use of antibiotics and reasonable microbiologi-
cal diagnostic, and to improve acceptance of ABS pro-
grammes. They have the objective of optimising the 
therapeutic and diagnostic management of patients with 
infection through greater adherence to recommenda-
tions. They should preferably take place as an active 
training measure rather than in the form of passive com-
munication of information (A).
Education, training and information in different formats 
and on various topics should be offered repeatedly as they 
are not sustainable as a one-off measure. They should be 
organised in agreement and integration with local ABS pro-
grammes (A).
Education, training and information should be independ-
ent of commercial interests, whereby the hospital admin-
istration is responsible for implementing and financing the 
measures (A).
Significance in practice:
•	 The target group for local training and educational ses-
sions should be clearly defined.
•	 The handling of conflicts of interest should be laid down 
in writing (Rules of Procedure) by the ABS team.
•	 Informative meetings and educational/training sessions 
should give special attention to a critical evaluation of 
published study results.
2.3  Conducting proactive audits of antiinfective use
Proactive on-site audits of antiinfective use in the context 
of antiinfective point-of-care chart reviews are important 
elements of ABS programmes and should be performed 
routinely by the ABS team (A). They enhance compliance 
with guidelines or clinical pathways, improve outcome 
in patients with infection and improve the quality of pre-
scribing with regard to indication, choice of agent, dos-
ing, dosing interval, administration route and treatment 
duration.
Depending on the problem and treatment target, besides 
point prevalence studies, agent-, indication- and/or diagno-
sis-related audits of antiinfective use should be conducted 
within the scope of regular antiinfective point-of-care chart 
reviews hospital-wide or at the unit level, whereby quality 
indicators should preferably be applied (A).
Results should be fed back in direct interaction with the 
prescribing physicians and discussed with them (A).
Significance in practice:
•	 Performing proactive audit of antiinfective use with 
review and feedback is time-consuming; it does, how-
ever, promote interdisciplinary collaboration.
•	 Antiinfective point-of-care chart reviews can increase 
the number of treatments complying with guidelines 
and thus substantially improve process quality.
2.4  Quality indicators
ABS programmes should be integrated within the hospi-
tal’s quality management. Content overlaps with the Thera-
peutics and Drugs Committee (drug safety) and Hospital 
Infection Control Committee (prevention of nosocomial 
infection) is useful and desired. Appropriate quality indi-
cators to measure prescription practice (process measure), 
emergence of resistance or trend in consumption (outcome 
measure) and structure ought to be set and applied in every 
ABS programme (B). At least three indicators measuring 
structural quality and at least three indicators measuring 
process quality should be set regularly (A).
Significance in practice:
•	 Quality indicators are used to evaluate the progress of 
an ABS programme.
•	 Quality indicators help to recognise hospital areas 
which will benefit from the implementation of targeted 
and intensive ABS measures.
3  Supplemental ABS strategies
3.1  Special programmes for treatment optimisation
3.1.1 De‑escalation A key aspect of supplemental meas-
ures is to streamline treatment after initial empirical broad-
spectrum therapy and conversion from empirical to targeted 
therapy. This ought to be done based on clinical criteria as 
well as microbiology results or other diagnostic findings. 
De-escalation measures ought to preferably be performed at 
the patient level in the context of antiinfective point-of-care 
chart reviews and proactive audits of antiinfective drug use 
(B). Programmes promoting antiinfective de-escalation are 
expected to, by reducing antibiotic load, impact beneficially 
on the emergence of resistance, the prevention of secondary 
infections, cost levels and adverse drug reactions (B).
Significance in practice:
•	 De-escalation includes conversion from an empirical 
combination therapy to targeted monotherapy based on 




•	 De-escalation should be initiated early on (after 48–72 h), 
which also includes discontinuation of initial therapy if 
diagnosis is not secured. Observational studies show that 
this strategy is not adopted in 20–60 % of cases.
•	 De-escalation programmes should point out that 
depending on the exact diagnosis in some cases instead 
of de-escalation, escalation may in fact be necessary.
3.1.2 Duration of treatment It is possible to shorten the 
duration of antiinfective treatment for many indications 
(e.g. perioperative antibiotic prophylaxis) and this is recom-
mended wherever backed by good studies and evidence. The 
ABS team should utilise local guidelines and antiinfective 
point-of-care chart reviews to draw attention to the exces-
sive duration of treatment frequently encountered in prac-
tice. The ABS team should define the duration of treatment 
recommended as a rule, since this is expected to impact sub-
stantially on antiinfective drug use, side effects and costs 
(A). Use of biomarkers such as Procalcitonin may be use-
ful for controlling the duration of treatment in cases where 
there is clinical uncertainty. As a result, the number of days 
of antibiotic therapy can be reduced and under certain cir-
cumstances costs can be cut (C).
Significance in practice:
•	 Shortening the duration of treatment appropriately 
reduces the density of antiinfective use without com-
promising clinical outcome or costs, it also minimises 
the emergence of resistance by decreasing selection 
pressure.
•	 The duration of treatment is well established for a num-
ber of indications, e.g. pneumonia, endocarditis, periop-
erative antibiotic prophylaxis. Therapy, thus, only needs 
to be individualised and extended in certain cases.
3.1.3 Parenteral‑to‑oral conversion If sufficient bioavail-
ability is assured, and if the patient’s condition allows, ther-
apy should be switched from parenteral to oral antibiotic 
application (A). This measure reduces the length of hospi-
tal stay and the risk of line-related adverse events. Further-
more, it leads to a reduction in the total cost of treatment. 
Implementation of programmes allowing parenteral-to-oral 
conversion of antimicrobial agents at the institutional level 
ought to be facilitated by developing clinical criteria and 
through explicit designation in institutional guidelines or 
clinical pathways (B).
Significance in practice:
•	 Switch to oral therapy should be assessed on day 3–4 of 
parenteral antiinfective therapy.
•	 Switching to oral therapy not only results in direct cost 
savings (antiinfective agents, supplies, nursing time) 
and lowers risk of line infections, it also increases the 
patient’s mobility.
3.1.4 Dose optimisation Adequate adjustment and opti-
misation of the dose and dosing interval is essential for 
effective, safe and responsible administration of antiinfec-
tive therapy, and an important part of ABS programmes. 
Besides individual patient factors, optimal dosing of antiin-
fectives should take into account the nature and severity of 
illness, the causative microorganism, concomitant medica-
tions, as well as the pharmacokinetics and pharmacodynam-
ics of the agents prescribed. Strategies to optimise dosing in 
ABS programmes should include assessment of organ func-
tion for drug dose adjustment in order to avoid adverse drug 
events and unwanted drug interactions (A).
Furthermore, optimising the dosing interval and duration 
of infusion is recommended in particular in critically ill 
patients, best by employing a therapeutic drug monitoring 
(TDM) scheme; appropriate consented local institutional 
guidelines should be available and up to date (B).
Significance in practice:
•	 Prolonged infusion of beta-lactams (taking into account 
physico-chemical stability) is reasonable and recom-
mended particularly in critically ill patients.
•	 TDM can avoid under-/over-dosing and minimise organ 
toxicity.
•	 Programmes for doses optimisation are cost-effective.
3.1.5 Scheduled switch of antimicrobials So-called 
“Cycling” programmes, which involve periodically remov-
ing a specific antimicrobial drug or an antimicrobial drug 
class as the standard recommended therapy and later reintro-
ducing it (periodic scheduled rotation), are not suitable as a 
strategy to reverse critical emergence of resistance or to con-
trol nosocomial outbreaks with multiple resistant pathogens 
and, as such, should not be used as a strategy to do so (A).
Strategic rotation of specific antimicrobial drugs or 
antimicrobial drug classes ought to be undertaken to limit 
the selective pressures and to achieve a reduction of infec-
tious microorganisms or microorganisms displaying spe-
cific resistance properties for a certain time (B). There is 
evidence to suggest that a balanced use of different antimi-
crobial drugs or antimicrobial drug classes (so-called “mix-
ing”) can minimise the emergence of resistance. In both 
cases, routine surveillance of antimicrobial drug use and 
resistance should be performed (A).
Significance in practice:
•	 Strategic rotation of specific antimicrobials or antimi-
crobial classes should be planned by the ABS team in 
consultation with the facility’s infection control team 
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and the microbiology department. Continuous surveil-
lance of pathogens, resistance patterns and consumption 
is imperative.
•	 Guidelines and antiinfective formularies that recom-
mend predominant use of fluoroquinolones or third-gen-
eration cephalosporins should be considered as critical.
3.2  Special rules for communication of microbiology 
results
The quality of microbiology diagnostics depends crucially 
on compliance with guidelines on procedures in the pre-
analytical phase. Expert consensus recommends that devia-
tions from protocol ought to be reported and the reasons for 
rejecting the samples stated (B).
Technical progress and up-to-date molecular diagnos-
tic methods for rapid pathogen detection should be used 
if they improve the quality of care and/or substantially 
improve identification and epidemiologic investigation of 
local outbreaks (A).
Positive blood culture findings, interim microscopic 
findings, results of rapid testing results and rapid suscepti-
bility testing should be communicated promptly to the phy-
sician (A).
Antibiograms ought to adhere to local guidelines with 
respect to antimicrobial use and diagnostic findings, be pre-
sented selectively in agreement with the ABS team, and, 
if need be, include relevant interpretative comments. This 
procedure aids selection of a targeted, guideline-based anti-
biotic regimen (B).
The microbiology laboratory is responsible for the timely 
identification of critical trends in antimicrobial resistance 
and prompt communication of observations to the ABS 
team and the physicians responsible for infection control 
(A). This way, the clinical and epidemiological significance 
of the observations can be defined at an early stage.
Significance in practice:
•	 Molecular diagnostic methods can expedite pathogen 
specification.
•	 Selective reporting of susceptibility results with respect 
to choice and number of antimicrobial agents, and com-
ments on daily treatment costs, route of administration, 
hospital formulary drug, resistance mechanisms sup-
ports adherence to local guidelines.
3.3  Special rules for management of patients 
with multidrug‑resistant microorganisms and C. 
difficile
ABS strategies should be used to prevent infection with C. 
difficile (A). Restricting use of certain antimicrobial drugs 
or substitution of antimicrobial drug classes (e.g. penicillin 
for cephalosporins or fluoroquinolones) can considerably 
reduce the incidence of C. difficile infection. Infection pre-
vention and control strategies are frequently also applied 
at the same time; however, they have less impact on the C. 
difficile incidence than in the epidemiology of MRSA or 
VRE.
Targeted ABS strategies are to varying degrees also 
effective in reducing multidrug resistant Gram-negative 
bacteria, particularly ESBL-producing microorganisms, 
MRSA and VRE, and ought to be specifically applied here 
too (B). In case of high prevalence of multidrug-resistant 
microorganisms, recommendations on diagnostic tests, 
evaluation of findings and treatment, as well as infection 
control management should be coordinated immediately 
and disseminated locally (A).
Routine surveillance of antimicrobial consumption and 
antimicrobial susceptibility data should be performed (A) 
to avoid indiscriminate compensatory use of other antimi-
crobial drug classes, since this can promote the uninten-
tional and uncontrolled emergence of resistance.
Significance in practice:
•	 Reducing consumption of cephalosporins and/or fluo-
roquinolones or substituting them for penicillin may 
reduce the frequency of C. difficile infection and pos-
sibly also have a beneficial effect on the incidence of 
infections caused by multidrug-resistant pathogens.
3.4  Computerised information technology
The ABS team should be supported by novel information 
and communication technology in the implementation of 
ABS programmes. Local treatment guidelines, the anti-
infective formulary, and other ABS documents should be 
available electronically (A).
Electronic prescribing tools with and without linkage 
to electronic preauthorisation solutions, to ABS docu-
ments or to active communication of information using 
computerised reminders to the prescriber should be used to 
improve the use of antiinfectives in the interest of patient 
safety (A). They ought to be used to reduce consumption 
and/or costs (B).
Computerised decision support systems that are inte-
grated into the hospital’s internal information system can, 
by utilising electronic medical records, help to evaluate and 
optimise the indication for antiinfective therapy, drug selec-
tion and dosing (C).
To implement computerised ABS measures, the ABS 
team must have hospital-wide access rights to electronic 




•	 The local treatment guideline and the antiinfective for-
mulary should be readily electronically accessible from 
every clinical computer workstation.
•	 For ABS activities or for surveillance and analysis of 
antimicrobial usage, computer physician order entry 
(CPOE) systems should be designed in such a way as to 
allow automated generation of exact lists of the antiin-
fectives used.
•	 Surgical software should be utilisable in such a man-
ner as to ensure that antibiotic prophylaxis is compliant 
with guidelines.
•	 Computer-based expert systems cannot replace a physi-
cian’s clinical judgement.
III  Recommendations of the guideline
1  Requirements
1.1  Availability of a team of ABS experts
In the community hospital setting, ABS programmes 
should be available hospital-wide, i.e. involving physicians 
across all operative and non-operative medical fields. A mul-
tidisciplinary team (so-called ABS team) of ABS-trained 
members (so-called ABS experts) is considered essential 
to the success of this type of programme. It should have the 
support of hospital administration, and collaboration of the 
infection control team and Therapeutics and Drugs commit-
tee, the pharmacy and of the responsible physicians (so-called 
ABS representatives) in the corresponding departments [2, 6]. 
The advantage of a multidisciplinary team is justified by the 
necessary diversity of ABS programmes which have differ-
ent objectives of interventions depending on hospital, type of 
ward and speciality discipline [26]. At least one randomised 
controlled [27, 28] and several prospective before-and-after 
studies [29–35] on the implementation of a trained ABS 
team, led to a decrease in mortality, a reduction in nosocomial 
infections and significantly shorter length of hospital stay. In 
addition, it resulted in an improved quality of prescribing, 
which in turn, led to fewer drug-related adverse events. The 
studies show that to achieve different objectives of interven-
tions it is crucial to collect data on clinical, microbiological 
and prescribing endpoints, and that this can only be done by 
appropriately trained and sufficiently qualified professionals. 
Based on the IDSA/SHEA guideline and past experience [6], 
the ABS team should include at least one infectious diseases 
physician and a clinical pharmacist, ideally with infectious 
disease training. The importance of an infectious diseases-
trained specialist and clinical pharmacist for effective ABS 
programmes was shown in several randomised, controlled 
as well as prospective, quasi-experimental studies. This was 
demonstrated particularly in regard to appropriate treatment 
of bacteremia [36], dosage adjustment and early conversion 
to oral therapy [37–40].
The ABS team should issue Rules of Procedure defining the 
organisational structures and conditions for implementation of 
antibiotic stewardship programmes including their functions 
and objectives. The composition of the multidisciplinary ABS 
team should be described in detail, from mandate to staffing 
(qualification, status, objectives and functions, competences and 
cooperations) and amount of time compensated. Organisational 
charts can be useful to show internal and external communica-
tion structures. The Rules of Procedure should stipulate the fre-
quency of meetings and the reporting obligations toward hospi-
tal administration. Potential conflicts of interest of members of 
the ABS team should be disclosed. Furthermore, it is necessary 
to lay down hospital-wide rules on how to deal with the phar-
maceutical industry or third parties because commercial market-
ing strategies may possibly influence antimicrobial prescribing 
[41–43].
Infectious diseases physicians are especially well-suited 
to planning and implementing ABS programmes and to 
developing guidelines because of their in-depth knowledge 
The guideline development group recommends:
For effective implementation of ABS programmes, 
it is essential that a multidisciplinary team should be 
instructed by the hospital administration and allocated 
with adequate resources to draw up guidelines derived 
by consensus with the users for the treatment of infec-
tious diseases and to ensure their implementation 
through ABS strategies (A).
The team should consist of at least one infectious 
diseases physician (or clinician with infectious diseases 
training) and an experienced clinical pharmacist/hospi-
tal pharmacist, as well as a specialist in microbiology, 
virology and infection epidemiology being responsible 
for laboratory diagnostic and microbiological consulta-
tion; furthermore, the physician locally responsible for 
infection control. The team members should either have 
appropriate training in antibiotic stewardship or already 
be sufficiently experienced (A).
The team will receive the support and collaboration 
of the hospital administration, and activities within the 
ABS programme should be compensated with a mini-
mum of one full-time equivalent (FTE) of 0.5 per 250 
beds (A). There should be good collaboration between 
the Therapeutics and Drugs Committee, Hospital Infec-
tion Control Committee, pharmacy and representatives 
of clinical divisions/departments (ABS representatives), 
for which purpose the team should issue its own Rules 
of Procedure (A).
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of the treatment of infectious diseases, their broad train-
ing in clinical internal or paediatric medicine, and not least 
their experience in conducting cross-departmental specialist 
consultations [43]. Infectious disease consultation services 
improved treatment quality in patients with bacteremia and 
in some studies also improved survival [36, 45–49]. In the 
case of community, nosocomial or ventilator-associated 
pneumonia, introduction of a consultation service in an 
intensive care unit (incl. training) resulted in shorter length 
of stay (13.8 vs. 19.2 days), a decrease of ventilation time 
(7.4 vs. 11.8 days), reduction in duration of therapy (9.2 vs. 
14.5 days) and a decrease in mortality by 6–13 % [27, 50] 
due to optimised empirical and targeted therapy strategies.
Several trails, including a randomised controlled trial, inves-
tigated the efficacy of a multidisciplinary ABS team which pro-
vides feedback to prescribing physicians. Particularly the feed-
back from the infectious disease consultation service resulted 
in a significantly more appropriate antibiogram-based therapy 
and in discontinuation of antimicrobial therapy [51–54].
Clinical pharmacists/hospital pharmacists are involved in 
the activities of the Therapeutics and Drugs Committee and 
in developing local guidelines and formularies. They have 
special knowledge of pharmacology—such as the clinical rel-
evance of adverse drug effects, dose optimisation or route of 
administration, and they have experience in conducting audits 
of antiinfective use, e.g. to ensure guideline adherence [37, 40, 
55–57]. Generally, the pharmacist is responsible for design, 
implementation, and compliance with formulary restrictions 
and preauthorisation requirements. He is also responsible 
for processing data on antimicrobial consumption and costs 
for the purpose of surveillance and benchmarking (pharma-
coeconomics) [8, 58–60]. Pharmacist-led parenteral-to-oral 
conversion programmes resulted in a significant reduction of 
parenteral therapy duration by 1–1.5 days without negatively 
impacting clinical outcomes [38, 39, 61]. This can, as shown 
in surgical departments of a German university hospital, lead 
to significant cost savings [62–64]. Computerised physi-
cian order entry systems (CPOE) could aid the pharmacist in 
reviewing the appropriateness of antiinfective prescriptions as 
these systems allow to produce a daily report on the antiinfec-
tives prescribed without review of individual patient charts on 
the ward.
Ideally, the team is complemented by a medical microbi-
ologist (in Germany: specialist in microbiology, virology and 
infection epidemiology; in Austria: specialist in infection 
control and microbiology) and the physician locally respon-
sible for infection control [65]. The expertise of the medi-
cal microbiologist is required to establish local guidelines 
for laboratory diagnostics of infection including preana-
lytical specimen management, and to report microbiological 
results in accordance with national and international quality 
standards. ABS interventions have to be in line with current 
microbiological diagnostics and reporting, as well as with 
easily accessible current surveillance data on pathogens. 
Medical microbiologists should provide support by using 
targeted diagnostic tests, rapid reporting and professional 
communication of results. Retrospective investigations indi-
cate that introduction of point-of-care chart reviews focusing 
on diagnostics delivered by medical microbiologists with 
infectious diseases training leads to significant reduction in 
the use of broad-spectrum antibiotics [66, 67].
If infectious diseases specialists are not available in 
smaller hospitals, an experienced hospitalist can, in col-
laboration with an authorised pharmacist who has at least 2 
years’ working experience in a hospital pharmacy, assume the 
leadership role in lieu of an infectious diseases physician. In 
this case, the team members must be ABS-trained, e.g. they 
must have completed training courses certifying them as 
ABS experts with knowledge in the following areas: design 
and implementation of ABS tools (treatment guidelines, anti-
infective formulary, treatment pathways), application and 
implementation of point prevalence surveys of antiinfec-
tive prescribing practices, requirements for surveillance data 
(consumption, pathogens, resistance), the content of current 
guidelines and important ABS intervention strategies. The 
ABS experts should be capable, as a team, of developing and 
implementing a programme for continuous improvement of 
the quality of antiinfective prescribing that is tailored to the 
specific needs and situation of the respective hospital. Rele-
vant continuous training in the field of ABS is recommended.
Based on the available evidence from the literature and 
repeated internal consultations, the guideline development 
group recommends that clinical infectious diseases physi-
cians or clinical pharmacists with ABS training should prin-
cipally assume core leadership function in the ABS team. 
Transferability of available experience (mainly American) 
to the German health care system is limited. The Ger-
man Society for Hygiene and Microbiology (DGHM) and 
the Paul Ehrlich Society for Chemotherapy (PEG) point 
out that the conditions in Germany (several years further 
training in medical microbiology, medical microbiologists 
working in hospital and also providing infectious disease 
consultation, likewise the shortage of infectious diseases 
physicians and specialised pharmacists) and experience in 
some other European countries (e.g. England and the Neth-
erlands) should allow to consider clinically oriented and 
experienced medical microbiologists (German: specialist 
in microbiology, virology and infection epidemiology), as 
being suitable for core leadership function, assumed they 
are for the most part present and available in the hospital 
and released from duties in the laboratory.
The team size depends primarily on the size of hospital. In 
the older and the current literature, between 0.5 and 1.5 full-
time equivalent posts depending on the number of beds (~200 
to ~900) or level of care provided, equating to one full-time 
equivalent of 0.5 per 250–300 beds, is well documented as 
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being cost effective and associated with high net savings in 
the initial phase [23, 27, 29, 68–71]. Ongoing activity by the 
teams is essential to preserve the effects, as the quality of use 
and cost usually deteriorate rapidly when ABS programmes 
are discontinued [23, 72]. In larger hospitals, it is therefore 
recommended to appoint department-specific ABS repre-
sentatives to support the ABS team in its activities. The ABS 
team must be involved in decision-making in the Therapeu-
tics and Drugs Committee and the Hospital Infection Control 
Committee as these committees may influence the design of 
ABS strategies, and jointly coordinated programmes (involv-
ing bundles of interventions) must be discussed to be effec-
tive particularly in the area of nosocomial infections. In the 
event of C. difficile outbreaks, or if the C. difficile incidence 
increase over time, infection control strategies alone are often 
not sufficiently effective. As demonstrated in multiple time-
series analyses, restricting use of cephalosporins, fluoroqui-
nolones or clindamycin is necessary to reduce C. difficile 
incidence effectively (see 2.1., 3.3.) [2, 25, 73].
The recommendations of the former ABS Group Austria 
on the further development of ABS programmes in Aus-
trian Hospitals (“Antibiotika-Kultur in Krankenanstalten”) 
[74], the IDSA/SHEA Guideline on “Hospital Antibiotic 
Stewardship” [6] and the Australian recommendations 
[43] refer to the need for hospital administration to direct 
the ABS team to plan ABS activities, to support the imple-
mentation of these interventions and to provide necessary 
resources. Several quasi-experimental before-and-after 
studies emphasise the importance of support given by the 
hospital administration or departmental management, in 
particular in the development of guidelines, their establish-
ment and successful implementation [75, 76].
1.2  Availability of surveillance data on pathogens, 
resistance, and antimicrobial consumption
1.2.1 Pathogens and resistance 
A requirement for successful ABS programmes is the 
availability of current hospital-wide data on pathogens and 
antiinfective use. This will allow for weak-point analysis 
and optimisation potential [2, 8, 77]. In addition to provi-
sion of routine reporting on pathogen identification with 
antibiogram, the microbiology laboratory is, in coordina-
tion with the ABS team, responsible for surveillance of 
pathogen and resistance patterns. Expert consensus rec-
ommends that pathogen-specific susceptibility data should 
be updated at least annually. Data on primary isolates and 
subsequent isolates should be presented separately. In addi-
tion, data should include susceptibility and resistance rates 
according to generally recommended breakpoints as well 
as the number of isolates tested. Electronic data process-
ing available in the microbiology laboratory can facilitate 
unit-specific (general ward vs ICU) or department-specific 
evaluation of resistance. This allows to recognise the distri-
bution of individual pathogens and antibiotic susceptibility 
profiles in different departments in dependence on prescrib-
ing habits, which helps guide ABS interventions.
The available infrastructure and personnel resources 
must allow even hospitals without an on-site microbiology 
laboratory, to provide hospital-based or unit-based data on 
pathogens and antimicrobial susceptibility, if need be, at 
shorter intervals, whereby presentation of data on suscepti-
bility rates on fewer than 10 tested isolates does not appear 
useful.
Expert consensus recommends reporting at least on S. 
aureus, E. coli other Enterobacteriaceae, P. aeruginosa and 
Candida spp. by specimen type (blood, urine and miscella-
neous samples) as well as on C. difficile, whereby screening 
culture results should be reported separately. Standardised 
surveillance is a fundamental requirement for benchmark-
ing with other institutions/departments. Interpretation of 
the data takes into account the size of hospital, the level 
of care, and the patient mix (e.g. hematologic-oncologic 
patients). Participation in established surveillance systems 
is recommended.
1.2.2 Antimicrobial consumption The guideline development group recommends:
Antimicrobial susceptibility data on major pathogens 
should be available and accessible at least yearly on a 
hospital-wide level and separately for general and inten-
sive care units, or department-specific, as the case may 
be. Data on primary isolates should be shown by patho-
gen and type of specimen, e.g. blood, urine, miscellane-
ous samples. Culture results from screening tests should 
be shown separately. Susceptibility rates should indicate 
the number of isolates tested. Infection rates should 
relate consistently to a single denominator (e.g. patient-
days/number of cases). Participation in an established 
surveillance system is recommended (A).
The guideline development group recommends:
Data on antimicrobial consumption, expressed as use 
density (daily doses per 100 patient-days) should be col-
lected at least annually or preferably quarterly and are 
generally reported by the pharmacist. Data are reported 
institution-wide, at the ward level as well as for individ-
ual (speciality) departments. On demand, data should be 
broken down to the agent level and should be provided 
to the ABS team. Participation in an established surveil-
lance system is recommended (A).
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Point prevalence surveys should be conducted for 
systematic quantitative and qualitative assessment of 
antiinfective use, and, if required should be reevaluated 
short-term (A). Antiinfective use data are collected at the 
patient level, allowing to assess prescribing quality based 
on indication and type of infection, and to recognise the 
need for targeted ABS strategies. Access to patient-level 
data ought to be guaranteed.
Continuous reporting of surveillance data on antiin-
fective consumption is useful in monitoring trends and 
identifying areas for evaluating appropriateness of pre-
scribing. It therefore supports systematic audit of anti-
microbial use with intervention and feedback to the pre-
scriber [78–80]. Consumption data are usually obtained 
from the pharmacy and are being presented as daily 
doses by the pharmacist. They are an essential prerequi-
site for medium and long-term assessment of the effec-
tiveness of interventions [81]. Another goal of continu-
ous surveillance is early identification of an increase in 
antibiotic consumption.
Expert consensus recommends that these data should 
be available institution-wide, for individual departments 
and at the ward level (e.g. general ward, intensive care 
unit) at least annually, preferably quarterly. Data should 
be collected by antimicrobial agents and reported in the 
form of daily doses per 100 patient-days (e.g. defined 
daily doses, DDD, according to the ATC Index of the 
WHO, and/or recommended daily doses, RDD) [82]. 
Upon the request of the ABS team, aggregate antibi-
otic usage data should be available for specific classes 
of antibiotics as well as stratified by different clinical 
units. Good examples for this form of data presentation 
such as so-called “antiinfective report” incl. graphical 
presentation are available for various German hospitals 
(Fig. 1).
Economic data (e.g. antibiotic costs) ought to be also 
documented; however, these data alone do not provide a 
suitable basis for analysis and intervention in terms of 
ABS. According to Article 23 (4) of the Infection Pro-
tection Act, usage data must be evaluated taking into 
account local resistance data and appropriate conclu-
sions must be drawn regarding the use of antibiotics. 
Furthermore, the necessary adjustments of antibiotic 
consumption must be implemented and the staff must 
be informed. Participation in an established surveillance 
system provides a standardised method to calculate anti-
microbial use density and is therefore recommended. 
Thus, depending on the patient mix, comparisons 
between different hospitals are also possible [81, 83]. 
However, IT-based patient-level consumption data, so-
called prescribed daily doses (PDD) should be the ulti-
mate goal.
Point prevalence surveys can be very helpful for tem-
porary assessment of the quality of antimicrobial prescrib-
ing, e.g. before and after guideline amendment [84–86]. A 
point prevalence survey provides information on the choice 
of substance, dose, dosing interval and route of adminis-
tration. In addition, data on the indication for prescribing 
(nosocomial vs community acquired or prophylactic) and 
the type of infection can be collected at patient level, allow-
ing to evaluate the consumption density in relation to the 
prescribing quality. The ABS team ought to have access 
Fig. 1  Graphical presentation of quarterly use density (RDD/100 patient-days) for different antibiotic classes
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to relevant patient data to conduct these surveys which 
are usually carried out as a 1-day point prevalence survey. 
Starting from the day of the survey, prescription data can 
also be collected retrospectively for a limited time interval 
(e.g. 6 days). On the day of the survey, patient-based data 
as mentioned above are documented. Additionally, it is rec-
ommended to document the number of patients per unit, to 
calculate the prevalence of antiinfective prescriptions per 
unit (e.g. ICU, department). This analysis allows to evalu-
ate the relation of defined daily doses recommended by the 
WHO (DDD) to prescribed daily doses (PDD) derived from 
chart review. Additionally, other patient-relevant infor-
mation can be investigated, e.g. on immunosuppression, 
organ insufficiencies or on presence of devices. European 
1-day point prevalence surveys (http://www.esac.be, http://
www.ecdc.europa.eu/en/healthtopics/Healthcare-associ-
ated_infections/database/Pages/database.aspx) have shown 
that approximately one-third of all hospitalised patients 
received antiinfective treatment and that even on regular 
wards >50 % of total consumption was given intravenously. 
Furthermore, within hospitals fluoroquinolones and cepha-
losporins were prescribed frequently, more than 30 % of 
the patients received combination therapy, and >50 % of 
perioperative prophylaxis was administered longer than 1 
day. Only 62 % of patients were treated in adherence with 
guidelines [85–87]. Point prevalence surveys can also 
be used to verify the feasibility of quality indicators (see 
Sect. 2.2.4).
2  ABS core strategies
Most previously published experience with ABS programmes 
in hospital shows that sustained efficacy can be achieved 
under the requirements mentioned above and on the basis of 
generally accepted strategies or bundles of strategies. Certain 
components of ABS programmes are considered and pri-
oritised as core ABS strategies, while others are considered 
optional or supplemental [2, 6, 22, 25]. The following core 
strategies are recommended by the guideline development 
group.
2.1  Application of local treatment guidelines/pathways, 
hospital antiinfective formulary, formulary restriction 
and approval requirements
pathogen and resistance patterns, and possibly drug 
costs. Drugs on the antiinfective formulary should be 
categorised according to recommended versus reserve 
or special compounds. In addition, these should be 
tagged with special prescription status and be subject 
to approval and preauthorisation requirements. The 
antiinfective formulary is updated at least yearly based 
on therapy guidelines and whenever necessary and 
approved by the Therapeutics and Drugs Committee 
(A).
Adherence to guidelines regarding substance selec-
tion, dosing, route and duration of treatment may 
improve clinical outcome in terms of mortality, as well 
as treatment duration and length of hospital stay. To 
ensure adherence, users should be involved in devel-
oping the guidelines and be educated through audits 
of antiinfective use or antiinfective point-of-care chart 
reviews (A).
Individualising antiinfective prescriptions with or 
without special approval requirements improves tar-
geted therapy and reduces inappropriate treatment. 
Various possibilities for implementation have been 
described and should be used, from simple antimicro-
bial order forms to highly differentiated antiinfective 
request forms that may be subject to specific time limits 
or limited to certain hospital areas (A). Guideline-based 
antiinfective drug use or use of individual defined sub-
stances can be controlled by this means, thus minimis-
ing consumption, costs and adverse drug events.
Restricting whole substance classes can—by shift-
ing to an alternative substance—prove to be an effec-
tive strategy for controlling nosocomial infections and 
the development of critical resistance levels; accord-
ingly, antiinfective restriction ought to be targeted (B). 
At the same time, routine surveillance of antibiotic 
consumption and locally prevalent pathogens and their 
susceptibility patterns should be performed to detect 
possible adverse effects of the strategy in time (A).
The guideline development group recommends:
Developing and updating local treatment guidelines, 
clinical pathways, and an antiinfective formulary is 
one of the ABS team’s chief responsibilities. The anti-
infective formulary should be based on national and 
international guidelines as well as on the local/regional 
Local treatment guidelines and clinical pathways are 
established and regularly updated by the ABS team with 
the involvement of the ABS representatives delegated 
from other clinical departments. National and interna-
tional guidelines, the patient mix and local microbiology 
and resistance patterns should be taken into account. The 
established or revised local guidelines should have institu-
tion-wide validity for which consensus must be obtained. 
The treatment guidelines are presented to the Therapeutics 
and Drugs Committee and the Hospital Infection Control 
Committee. It is recommended to provide local treatment 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































guidelines in electronic or pocketbook format and to 
ensure acceptance among users through training and edu-
cation [88]. Without these measures guideline adherence 
is rather poor, and effects in terms of improving clinical 
outcomes or other endpoints remain small [89].
Treatment guidelines or clinical pathways can improve 
outcomes related to mortality, length of hospital stay 
and duration of treatment [90, 91]. High adherence to 
guidelines or clinical pathways, e.g. for management 
of community-acquired or nosocomial pneumonia, can 
be achieved with training and education. Thus, mortal-
ity can be decreased and the medium duration of therapy 
and hospital stay can be shortened by 1.7–6.8 days, while 
antiinfective usage is reduced by up to 77 % [92–98]. Vari-
ous strategies of treatment optimisation have been stud-
ied for community-acquired or nosocomial pneumonia 
[99–102] and have partly been addressed in international 
and national guidelines. Their implementation in local 
guidelines, guideline adherence assumed, can help to avoid 
that therapy is either too broad or too long. An American 
and a French observational study have shown that involv-
ing physicians in the development of local guidelines can 
improve acceptance. When local consensus guidelines 
were posted on the intranet and regularly distributed to 
physicians and presented in departmental staff meetings, 
guideline-conform management of nosocomial pneumonia 
increased from 46 to 81 %, and 14-day mortality dropped 
from 23 to 8 % [103]. In a study of endocarditis, compli-
ance with antimicrobial therapy improved from 23 to 62 % 
and 1-year mortality significantly decreased from 19 to 8 % 
[104] (Table 1). Numerous new investigations on improv-
ing guideline compliance have shown that institutionalising 
guidelines can optimise the quality of therapy in different 
categories (e.g. dose adjustment to renal function, paren-
teral-to-oral conversion, timely administration) by about 10 
or more percent [105–110]. 
Clinical pathways complement local treatment guide-
lines, often taking into account diagnostic algorithms and 
risk scores. They are designed as a flowchart to simplify 
and improve the management of patients with infectious 
diseases. In a controlled, multi-centre Canadian study a 
risk score (PSI, pneumonia severity index)-based clinical 
pathway was instituted, addressing criteria for inpatient 
admission, sequential therapy and discharge of patients 
with community-acquired pneumonia. Although patients 
in the “experimental” arm had more severe disease, hos-
pital stay and duration of parenteral antibiotic therapy 
was significantly shortened in this patient group, and the 
patients received monotherapy significantly more often 
without negative impact on mortality. Within this frame-
work, an Australian study showed an approximately 10 % 
reduction in the use of broad-spectrum antibiotics [93, 
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observational study in the UK, where introduction of a risk 
score (CURB-65)-based clinical pathway for treatment of 
community-acquired pneumonia influenced prescribing 
behaviour. As expected, CURB65-guided therapy resulted 
in an overall reduction in the prescription of cephalospor-
ins and macrolides by 19 and 14 %, respectively, without 
negatively affecting outcome (30-day mortality, clinical 
response, treatment outcome). There was a correspond-
ing increase in use of aminopenicillin monotherapy, and 
guideline compliance increased from 25 % to over 60 % 
[113].
Acceptance and implementation of treatment guide-
lines not only improves by involving users in guideline 
development. Other supplemental ABS strategies such as 
repetitive education, training and audits of antibiotic pre-
scribing with feedback to the prescriber improve accept-
ance and adherence [114]. This is shown by a controlled 
before-and-after study in which adherence was consist-
ently improved by a combination of interventions involv-
ing distribution of information packs to staff, repeated 
compilation of prescription data and educational ses-
sions followed by reminders in the form of posters [98]. 
Implementation of a uniform guideline for perioperative 
prophylaxis including recommendations for choice of 
agent, dosage and timing resulted in annual antimicrobial 
cost savings of approximately USD 112,000 in a 1400-
bed hospital [115].
The institutional antiinfective formulary is established 
by the pharmacist in the ABS team based on therapeutic 
efficacy, toxicity and cost. Drugs of the formulary should 
be categorised into recommended versus reserve or spe-
cial compounds depending on local treatment guidelines. 
Graphical overview with alerts (traffic light system), infor-
mation on daily therapeutic costs or restrictions on use is 
advisable. Adding information on special prescription or 
approval requirements is desirable. Besides information on 
agent and trade names, these lists contain information on 
the recommended daily dose, including dose adjustments 
in regard to organ impairment (Table 2). The antiinfective 
formulary must be passed by the Therapeutics and Drugs 
Committee. The formulary has an immediate influence on 
prescribing behaviour [116].
Caution should be exercised in controlling antibiotic 
use via the formulary alone without an indication-based 
Table 2  Example of a 
formulary
Antibiotic (AB)- Group Appl. Trade Name Active agent Recommended daily dose RDD DTC
Normal renal function











3 x 10 million IU
or 4 x 5 million IU
3 x 1 million IE
2 x 10 million IU









3 x 2 g
3 x 1 g
2 x 2 g















3 x 2000/1000 mg
3 x 500/125 mg
2 x 2000/1000mg 
3 x 500/125 mg
€€
€








3 x 4g/0,5 g 2 x 4g/0,5 g €€
Carbapenems i.v. Meropenem Meropenem 3 x 1 g
for meningitis:
3 x2 g





















1 x 5-6 mg/kg KG











3 x 500 mg
3 x 400 mg
3 x 500 mg









2 x 600 mg
2 x 600 mg
2 x 600 mg









The recommended daily dose refers to an adult patient (~ 70 kg)
Red: Special
Antibiotic, Confer with 
senior physician
DTC: Daily Therapeutic Cost
DTC: €: 0 to €2;  €€: 2 to €10;  €€€: 10 to €25; €€€€: 25 to €50;  €€€€€: more than 50 € to
€150 
Bold Available oral antibiotics
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treatment concept and concomitant surveillance of anti-
biotic consumption and resistance. It was for instance 
observed that by adding levofloxacin to the antiinfective 
formulary fluoroquinolone use subsequently increased sub-
stantially, resulting in a higher rate of MRSA infection. 
When an alert was inserted next to the fluoroquinolone 
selections on the electronic order entry screen, indicating 
alternative antibiotic agents in accordance with local guide-
lines, levofloxacin use decreased again by 50 % from 12 
to 6 DDD/100 patient-days and the MRSA infection rate 
decreased again from 1.37 to 0.63 cases per 1000 patient-
days [117]. Similar effects have been observed for other 
substances and classes and pathogens [118, 119].
Individualised antiinfective orders with or without 
approval requirements extend from simple to highly dif-
ferentiated, computer-assisted order forms with an auto-
matic prescription stop after a defined time (so-called 
“automatic stop order”). These can be agent, patient or 
indication based, temporary or limited to certain hos-
pital areas. Individualised antiinfective orders present 
an effective tool to quickly and effectively influence 
prescribing behaviour. Special order forms or approval 
requirements are usually implemented for broad-spec-
trum antibiotics, new/expensive substances or substances 
requiring extensive consultation. They require justifi-
cation for prescription, which must be evaluated prior 
to approval, and can effectively control use and costs. 
These substances are separately marked in the antiinfec-
tive formulary.
Many older prospective before-and-after trials dating 
from the 1980s and 1990s documented that restricting use 
of new and expensive cephalosporins generated cost sav-
ings of between 19 and 46 %, and reduced consumption by 
up to 50 % [6, 120–124]. Significant cost reductions being 
achieved through an antimicrobial-restriction policy are 
less commonly observed in recent years, because numerous 
antibiotics have lost patent protection. Nevertheless, more 
recent studies showed continuing effectiveness regarding 
reduction in antibiotic consumption of as much as 54 %. 
[23, 125–127]. Newer research on restricting use of broad-
spectrum antibiotics yielded a monthly reduction from 137 
to 72 DDD/100 cases or from 181 to 102 DDD/1000 patient-
days, respectively. Overall, after implementation, the ABS 
programme delivered effective cost savings of USD 300,000 
p.a. (corresponding to net savings of USD 2350/100 cases or 
2182/1000 patient-days, respectively). [59].
Use of special order forms limiting antibiotic dura-
tion has proved to be particularly effective within the 
field of perioperative antibiotic prophylaxis. In several 
prospective, quasi-experimental before-and-after stud-
ies the effect of automatic stop order forms on antibiotic 
consumption, costs and guideline adherence to avoid 
extended prophylaxis was evaluated. By educational 
training, an overall 20–30 % improvement in guideline 
adherence was observed with respect to choice of drug 
and duration of antimicrobial use, with one study also 
showing improvement in appropriate timing of perio-
perative antibiotic prophylaxis before incision. This 
resulted in a reduction of surgical site infections from 3.2 
to 1.9 %, a reduction in cost of USD 3000/100 patient-
days and a reduction in consumption of approximately 20 
DDD/100 patient-days [128–132]. Other equally effective 
automated stop orders limiting total duration of treatment 
(e.g. 14 days) or restricting duration of reserve drugs such 
as vancomycin or carbapenems (72 h for empiric therapy, 
7 days for therapeutic indication) have been described. 
Treatment beyond was only possible following consulta-
tion with the infectious diseases specialist or pharmacist. 
As a result, consumption of these substances was reduced 
by 10–25 % [125, 133, 134].
Specific programmes to restrict antimicrobial use can 
minimise nosocomial infections (e.g. C. difficile) and the 
increase of resistant pathogens (ESBL, MRSA) by a rapid 
and marked alteration in consumption. However, such pro-
grammes are usually only temporary and lack sustainable 
efficacy [22]. Restriction strategies are adopted in coordi-
nation with the Therapeutics and Drugs Committee, Hos-
pital Infection Control Committee, the pharmacy, and hos-
pital management. Timely and continuous surveillance of 
consumption, infectious diseases and resistance data are 
to be assured, to monitor compliance, but also to be able 
to rapidly identify possible negative impacts. The impor-
tance of instituting a programme for the surveillance of 
antimicrobial use including unrestricted antibiotics, cost 
and the development of resistance demonstrated by a pro-
spective quasi-experimental observational study at a 450-
bed hospital in Greece. In the study, use of carbapenems, 
third-generation cephalosporins, and fluoroquinolones was 
restricted based on a national recommendation in context 
of growing resistance among Gram-negative microorgan-
isms. As a result, ciprofloxacin and ceftazidime consump-
tion decreased as desired by 28 and 42 %, respectively. 
Subsequently, susceptibility of P. aeruginosa (32–45 %) 
and E. coli (77–84 %) to ciprofloxacin increased. On the 
other hand, susceptibility of K. pneumoniae to ciprofloxa-
cin (80–60 %) and ceftazidime (61–46 %) continued to 
decrease. Of note, piperacillin/tazobactam use increased by 
271 % and overall costs and consumption were 12–13 % 
higher than before intervention [135, 136].
Programmes restricting use of cephalosporins and fluo-
roquinolones have been repeatedly examined for their “eco-
logical” effects [137–140]. Multicenter controlled investi-
gations in France show a 90 % reduction in fluoroquinolone 
use after introduction of a time-limited restriction, resulting 
in a significant reduction in MRSA. Reintroduction of fluo-
roquinolones was associated with a significant increase in 
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MRSA compared to the previous period [141, 142]. A new 
study from France shows that even less restrictive fluoro-
quinolone use (20 % reduction) combined with improved 
hand hygiene also reduces the rate of MRSA (moderate) 
and at the same time impacts positively on resistance of P. 
aeruginosa to fluoroquinolones [143]. Other new studies 
demonstrate effects of changes in fluoroquinolone prescrib-
ing practice on C. difficile-associated diarrhoea [144–148]. 
The effects, however, are not always due to the fluoroqui-
nolone reduction alone.
2.2  Design and implementation of education, training 
and information
1.7 to 0.6 per 1000 patient-days, while in another study a 
significant reduction from 74 to 17 % was seen [153, 154]. 
In Canadian long-term health care facilities, a 1-year long 
educational intervention involving repeated mailing of anti-
biotic guidelines with feedback on individual antibiotic 
prescribing behaviour of urinary tract infection, pneumo-
nia, skin and soft tissue infection and sepsis resulted in a 
significant 64 % reduction of nonadherent treatment com-
pared to control facilities [155]. Nonadherent antibiotic 
prescriptions remained lower during follow-up, although 
after termination of the educational intervention, the effect 
was no longer significant compared to control facilities. A 
similar effect was achieved in a study on an educational 
programme for guideline-based treatment of respiratory 
tract infections in emergency departments, in which 1 year 
post-intervention a 10 %, albeit non-significant reduction in 
antibiotic consumption was still documented compared to 
sites without intervention [156].
With the aim of reducing extended use of perioperative 
antibiotic prophylaxis by means of information dissemi-
nated by e-mail, poster and lectures, 12 Australian hospitals 
succeeded in rapidly and effectively limiting the duration 
of antibiotic prophylaxis to maximally 48 h, thus achieving 
considerably lower costs, which more than outweighed the 
costs of the 1-year intervention [157]. However, the effect 
of the intervention rapidly declined with time, as seen in 
other studies [158]. Repeated guideline-based educational 
interventions are necessary. They were shown to be particu-
larly effective in optimising perioperative antibiotic prophy-
laxis [6, 159]. In an Argentine multi-step ABS programme 
involving training and formulary restriction, antimicrobial 
consumption could be reduced from 43 to 28 DDD/100 
patient-days, resulting in substantial savings (>900.000 
USD) over 18 months. During the training period a signifi-
cant increase in the rate of prescriptions based upon micro-
biology results (27–63 %) was found, and use of ceftriaxone 
and carbapenems subsequently more than halved [30]. The 
combination of one-on-one education (academic detail-
ing) and special review of orders for either levofloxacin or 
ceftazidime was also seen as a highly effective method for 
reducing inadequate antibiotic use. Unnecessary antibiotic 
prescription was significantly reduced by 41 % with no 
change in clinical outcome [28, 160]. However, academic 
detailing is time-consuming and personnel-intensive [28, 
160]. This can partly be compensated by less time-consum-
ing feedback activities, e.g. in the form of written recom-
mendations placed in the patient chart; however, these are 
not quite as effective and less sustainable [157].
Education, training and information should be independ-
ent and should not be guided by the commercial interests 
of the manufacturers of medical and diagnostics products, 
since this is the only way to ensure that prescribing and 
professional behaviour are not subject to direct or indirect 
Education, training and information should be independ-
ent of commercial interests, whereby the hospital admin-
istration is responsible for implementing and financing the 
measures (A).
Education, training and information are essential ele-
ments of every ABS programme. Overall, in a systematic 
review active clinician education in the form of lectures, 
seminars, “bedside teaching” demonstrated greater effec-
tiveness than passive education techniques like posters, 
pocket cards or written prescription recommendations 
[149]. Two multicenter, randomised, controlled, and some 
before-and-after studies demonstrated that an educational 
intervention improved compliance with guideline-recom-
mended diagnostic, therapeutic and prophylactic measures 
and resulted in a reduction in the number of non-indicated 
treatments [150–152]. By educational training of nurses 
and medical staff inappropriate submission of urine cul-
tures decreased from 2.6 to 0.9 per 1000 patient-days; 
treatment of asymptomatic bacteriuria was reduced from 
The guideline development group recommends:
Targeted education, training and information are 
essential elements of any ABS programme. They pro-
vide the foundation of knowledge needed to promote 
more rational use of antibiotics and reasonable micro-
biological diagnostic, and to improve acceptance of 
ABS programmes. They have the objective of opti-
mising the therapeutic and diagnostic management of 
patients with infection through greater adherence to 
recommendations. They should preferably take place 
as an active training measure rather than in the form 
of passive communication of information (A).
Education, training and information in different for-
mats and on various topics should be offered repeatedly 
as they are not sustainable as a one-off measure. They 
should be organised in agreement and integration with 
local ABS programmes (A).
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influence (Table 3). A systematic review examined the 
impact of various strategies undertaken by the pharmaceu-
tical industry such as visits, funding for travel or lodging, 
sponsoring educational events, free samples, etc., on pre-
scribing practices. According to the study, industry-spon-
sored continuing medical education (CME) had the big-
gest impact on physician prescribing practices compared to 
other activities, leading to a 6–19 % increase in prescrip-
tion rates of the sponsor’s medication [41, 42]. The respon-
sibility of organising, holding and financing educational 
events should be assumed by hospital management.
2.3  Conducting proactive audits of antiinfective use
physicians reasons for choice of drug could be asked for and 
therapy should be optimised based on clinical, laboratory, 
radiological and microbiological examination results. Con-
comitant disease, comedication, expected pathogens when 
microbiology is not yet known and local antimicrobial suscep-
tibility patterns must be taken into account. The guideline of 
two North American medical societies has described this type 
of audit as a highly effective interventional tool that provides a 
core strategy for an antimicrobial stewardship programme—
called “prospective audit with intervention and feedback” [6].
Proactive audit of antiinfective use with review and feed-
back by an ABS team has been described as effectively 
increasing the rate of adequate antiinfective use by 20 %; 
the strategy can reduce the rate of inadequate use by half 
[34, 53, 161–164]. Methods of feedback can be modified, 
especially when computer-based assistance is available 
[165]. The quality of information is important; however, 
personal feedback is often more effective [165, 166]. In 
addition to a direct improvement in the quality of prescrib-
ing, audits of antiinfective use allow to recognise the need 
for education and training.
Audits of antiinfective use can be agent-, diagnosis- or 
indication-based and can be performed at the patient level, 
in individual departments, wards, or hospital-wide. Tar-
geted (e.g. in relation to agent, speciality department or 
ward) as well as time-restricted antiinfective audits can be 
highly effective (examples are shown in Table 4). A pro-
gramme in which an infectious diseases specialist or phar-
macist conducted targeted point-of-care chart reviews (3×/
week) of patients receiving multiple antibiotics, prolonged 
or high-cost therapy (120-bed hospital), achieved good 
acceptance: 69 % of the recommendations were accepted 
and implemented, of these 38 % were to discontinue 
Table 3  Examples of the influence of commercial interests on prescribing and formulary design [41, 42]
Meetings with pharmaceutical representatives 66 % less likelihood of prescribing generic products
Travel sponsoring (congresses, etc.) Requests to add the sponsor’s drugs to the hospital formulary are associated with an odds ratio 
of 7.9 % (95 % CI, 1.1–55.6)
4.5- to 10-fold increase in hospital prescribing rate (sponsor’s products) as compared to before 
travel
Continuing medical education (CME funding) Prescribing rate, (sponsor’s products) increases by 5.5–18.7 %
Research funding Requests to add the sponsor’s drugs to the hospital formulary is associated with an odds ratio of 
9.5 (95 % CI, 2.6–35.7)
Table 4  Examples for performing targeted proactive audits of antiin-
fective use
• Perioperative antibiotic prophylaxis in selected surgical fields
• Targeted therapy of bacteremic patients hospital-wide
• Community-acquired pneumonia in the emergency department
• Sequential therapy on general wards with antibiotics of high 
bioavailability
The guideline development group recommends:
Proactive on-site audits of antiinfective use in the con-
text of antiinfective point-of-care chart reviews are 
important elements of ABS programmes and should 
be performed routinely by the ABS team (A). They 
enhance compliance with guidelines or clinical path-
ways, improve outcome in patients with infection and 
improve the quality of prescribing with regard to indica-
tion, choice of agent, dosing, dosing interval, adminis-
tration route and treatment duration.
Depending on the problem and treatment target, 
besides point prevalence studies, agent-, indication- and/
or diagnosis-related audits of antiinfective use should be 
conducted within the scope of regular antiinfective point-
of-care chart reviews either hospital-wide or at the unit 
level, whereby quality indicators should preferably be 
applied (A).
Results should be fed back in direct interaction with pre-
scribing physicians and discussed with them (A).
Proactive audit of antiinfective use with review and feed-
back include the collection and analysis of data on diagnosis, 
indication, choice of agent, dosing, administration route and 
treatment duration at patient level. The results are fed back to 
and discussed with the prescribing physicians (point-of-care 
interventions). In personal consultation with the prescribing 
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therapy due to excessive duration, duplicate coverage or 
inappropriate use, and 33 % were to switch to oral appli-
cation. Compared with the previous year, a cost reduction 
of 19 %, estimated savings of USD177,000 were achieved 
[167].
Agent-related proactive audit of antiinfective use can 
address dose adjustment to organ dysfunction, switch to oral 
application, discontinuation of therapy or targeted therapy 
based on microbiology. In a multicenter, randomised, con-
trolled study parenteral antibiotics could be significantly 
reduced by 1 day when patients who had received paren-
teral antibiotics for longer than 3 days were reviewed by an 
infectious diseases physician for possible sequential therapy 
based on defined clinical and laboratory criteria and a rec-
ommendation was made for switch to oral drug application 
[38]. The intervention showed lack of effect on length of 
hospital stay, but reduced mean antibiotic costs per patient 
significantly from USD 36 to USD 20. Following updated 
recommendations on aminoglycoside treatment, antiinfec-
tive visitations by infectious diseases physicians achieved a 
significant 11 % reduction in nephrotoxicity by shortening 
the treatment duration from 6 to 4 days and optimise dos-
ing by monitoring drug levels [161]. In a study assessing 
the effects of intervention and feedback by the infectious 
diseases physician, empiric treatment with levofloxacin, 
vancomycin and carbapenems was switched to targeted 
antibiotic treatment in line with guidelines. Consumption 
subsequently decreased by 20 % and median duration of 
therapy was reduced from 6 to 4 days in comparison to a 
control group [168, 169]. In another intervention, a pro-
spective audit and feedback programme was instituted in 
a teaching hospital by pharmacists and infectious diseases 
physicians to counteract a trend towards increasing use of 
expanded-spectrum antimicrobials. This resulted in a sig-
nificant reduction in consumption of third-generation cepha-
losporins and aztreonam within a period of 6 years from 28 
to 6 DDD/1000 patient-days. Furthermore, there was a sig-
nificant decrease over time in infections caused by C. diffi‑
cile from 2.2 to 1.4 cases/1000 patient-days [29]. According 
to another recent time-series analysis, a significant decrease 
in fluoroquinolone consumption from 118 to 78 DDD/1000 
patient-days over 4 years was achieved by the ABS team 
following implementation of daily hospital-wide audits of 
fluoroquinolone use based on individual patient data. At 
the same time, the rate of fluoroquinolone-resistant P. aer‑
uginosa continuously decreased from 42 to 26 % [143]. 
A similar intervention in intensive care units resulted in a 
sustained 22 % decrease in the number of days of therapy 
with extended spectrum antibiotics compared with the con-
trol group—without negative impact on mortality [170] 
(Table 5).
With proactive audit of antimicrobial use focussing on 
diagnosis and indication for antibiotic treatment by an 
infectious diseases physician-led ABS team with direct 
interaction and feedback as well as written documenta-
tion of recommendations, length of stay was shortened by 
3.3 days and a 6 % decrease in mortality was achieved [27]. 
As a result of the intervention, median hospital costs were 
reduced by USD 2642/intervention. By optimising the pro-
cess of perioperative antibiotic prophylaxis, appropriate 
dosing and timely administration significantly increased 
from 72 to 90 % and 36 to 79 %, respectively [171]. Within 
the frame of quality assurance, and for benchmarking pur-
poses with other hospitals, targeted audits of selected pro-
cess of care indicators for the management of important 
and frequent infections can also in small acute-care hos-
pitals lead to a significant improvement in adherence to 
established guidelines. In a quasi-experimental before-and-
after study of a total of 36 hospitals (<200 beds) the effect 
of proactive audit and feedback, by using quality indica-
tors, on the management of pneumonia in the emergency 
department was investigated. The hospitals demonstrated a 
Table 5  Suggested evaluation 
categories in local audits of 
antimicrobial use
1. Antimicrobial therapy adheres to established institutional guidelines with respect to:
 Choice of agent
 Dose
 Route of administration
 Duration of infusion
 Duration of treatment
2. Antimicrobial prophylaxis adheres to established institutional guidelines with respect to:
 Choice of agent
 Dosing
 Route of administration
 Timing of preoperative dose
 Dosing interval
 Duration of administration
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30 % improvement in the performance of microbiological 
diagnostics (blood/sputum cultures) prior to therapy and 
antibiotic administration within 4 h of hospital admission. 
As a consequence, mortality was reduced significantly by 
12–6 % [172]. Proactive audits of antiinfective use based 
on selected quality indicators should regularly take place 
(see Sect. 2.2.4).
The ABS team should determine the objective, type, 
contents and frequency of point-of-care chart reviews in 
agreement with the wards or departments involved and 
should give report on its effects. The ABS team should get 
project-specific to hospital-wide access to the laboratory, 
radiological and microbiological data needed. Computer-
based information technology can facilitate audits of anti-
infective use (see Sect. 3.3.4)
2.4  Quality indicators
community-acquired pneumonia and urinary tract infec-
tions. However, numerous suggestions have been put for-
ward for indicators whose evidence base is rather small 
and whose relevance and practicability rests on consensus 
alone. In Germany, there are catalogues of quality indica-
tors for instance for the Helios Hospital Group (“Initiative 
of Quality Medicine”) or for the Rhön, Sana und Asklepios 
Hospital Group (“Quality Hospitals”). They also exist for 
mandatory external health care quality assurance concepts, 
for whose development and implementation the German 
National Institute for Quality Measurement in Health Care 
(Bundesgeschäftsstelle Qualitätssicherung gGmbH; BQS) 
till 2009, and since then the AQUA Insitut (the Institute 
for Applied Quality Improvement and Research in Health 
Care GmBH) was commissioned by the Federal Joint Com-
mittee (Gemeinsamer Bundesausschuss; G-BA). However, 
only few quality indicators have been set for measure-
ment of antibiotic prescribing of which some are already 
at goal (e.g. for community-acquired pneumonia, antibiotic 
prophylaxis for obstetric and gynaecological indications, 
femur fracture, as well as hip and knee endoprosthesis). 
Individual more or less plausible and consented catalogues 
of structural indicators are available outside Germany [65, 
173, 174]. A lot of experience was especially gained in 
France. Process quality indicators, respective pneumonia 
and surgical prophylaxis, are available in multiple countries 
(e.g. http://www.qualitymeasures.ahrq.gov or http://www.
jointcommission.org or http://www.ic.nhs.uk).
The guideline committee in collaboration with the ABS 
Expert Network (http://www.antibiotic-stewardship.de) and 
the University Hospital of Freiburg established a catalogue 
of consensus structural and process ABS quality indica-
tors in a multistage procedure including Delphi survey. 
The catalogue should facilitate external and internal quality 
assurance. Clinical, ecological (resistance) and economi-
cal (cost, cost-effectiveness) relevance as well as the pre-
sumed practicability were assessed separately in several 
categories. In analogy with the so-called QUALIFY pro-
cess [175], a provisional list of potentially suitable struc-
tural and process indicators was drafted. It was based on 
the draft of the Guideline itself, the current literature [1, 
6, 25, 86, 105, 171, 176–189], including documents and 
experience with the former ESAC Group (http://www.esac.
ua.ac.be) [190] and the former ABS International Group, 
an initiative of 9 EU member states for the improved use 
of antiinfectives (http://www.abs-international.eu) [191]. 
Based on the results of a workshop (15 participants) held 
at the ABS Expert Network meeting in November 2011 
in Freiburg, a later questionnaire survey (Delphi methods, 
n = 75 ABS experts, i.e. advanced members of the ABS 
training programme of varying professional background, 
incl. pharmacy and microbiology) and a further workshop, 
of the initial 99 potential indicators 67 were put forward for 
The guideline development group recommends:
ABS programmes should be integrated within the hos-
pital’s quality management. Content overlaps with the 
Therapeutics and Drugs Committee (drug safety) and 
Hospital Infection Control Committee (prevention of 
nosocomial infection) is useful and desired. Appropriate 
quality indicators to measure prescription practice (pro-
cess measure), emergence of resistance or trend in con-
sumption (outcome measure) and structure ought to be 
set and applied in every ABS programme (B). At least 
three indicators measuring structural quality and at least 
three indicators measuring process quality should be set 
regularly (A).
ABS programmes are to be regarded as a strategy to 
ensure quality and should preferably reside as a standard 
component within the hospitals’ existing quality manage-
ment [25]. It is recommendable to utilise data captured pur-
suant to the new Infection Protection Act for surveillance 
of resistant microorganism or antiinfective drug use (IfSG 
§23 Abs. 4) as well as selected data on infection manage-
ment provided by external quality assurance sources. Addi-
tional quality indicators for local use should be selected 
and applied regularly. This allows to evaluate and docu-
ment whether ABS aims can be met [171]. Owing to the 
different structures and organisation of hospitals, ABS 
measures must be evaluated locally and if need be adjusted 
accordingly [2, 22].
Ideally, indicators ought to be evidence-based, i.e. 
guideline-derived, and ought to be supported by a for-
mal consensus process in regard of their relevance and 
practicability; last but not least, they ought to be also put 
to the practical test. Indicators have been developed for 
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discussion and 21 structure and 21 process indicators subse-
quently selected as presumably most suitable (see Tables 7, 
8 in the Appendix) [434]. Suitable indicators on the quality 
of antimicrobial prescribing (process indicator) and struc-
ture (structure indicator) taken from this list (Tables 7, 8 in 
the Appendix) ought to be set and used in every ABS pro-
gramme. At least three indicators on structure and process 
quality each should be determined regularly.
3  Supplemental ABS strategies
There are various strategies or measures that can supple-
ment and complement the core ABS activities described 
here. They can play a pivotal role in further improvement 
of outcomes of antibiotic stewardship programmes. Sup-
plemental ABS strategies include special programmes and 
recommendations for therapy optimisation, special rules in 
reporting microbiology results, rules on the management 
of patients with multidrug-resistant pathogens (MDR) or 
C. difficile as well as computerised support systems. Evi-
dence for their effectiveness varies. Their implementation 
partly depends on the hospital’s infrastructure, e.g. with 
computerised expert systems and information technology 
or the possibility for rapid measurement of antibiotic levels 
in serum.
3.1  Special programmes for treatment optimisation
As a rule, programmes for therapy optimisation such as de-
escalation (streamlining) strategies, interventions to control 
duration of treatment, switch to oral administration and 
optimisation of antimicrobial dosing are carried out at the 
ward or patient level (also called “point-of-care interven-
tions”). These are relatively focussed interventions that can 
be highly effective in improving the quality of antimicro-
bial prescribing. They are usually elements of proactive 
audit of antiinfective use or chart review, implementation 
can, however, also be computerised. [2, 22, 25].
3.1.1 De‑escalation 
de-escalation are expected to, by reducing antibiotic 
load, impact beneficially on the emergence of resist-
ance, the prevention of secondary infections, cost levels 
and adverse drug reactions (B).
The guideline development group recommends:
A key aspect of supplemental measures is to streamline 
treatment after initial empirical broad-spectrum therapy 
and conversion from empirical to targeted therapy. This 
ought to be done based on clinical criteria as well as 
microbiology results or other diagnostic findings. De-
escalation measures ought to be preferably performed 
at the patient level in the context of antiinfective point-
of-care chart reviews and proactive audits of antiinfec-
tive drug use (B). Programmes promoting antiinfective 
De-escalation proposes to simplify treatment, i.e. mono-
therapy rather than combination therapy, targeted (narrow 
spectrum) rather than untargeted broad-spectrum therapy, 
discontinuation of empiric treatment if diagnosis is uncer-
tain [192, 193]. There are insufficient data to favour combi-
nation therapy over monotherapy in the routine management 
of ventilator-associated pneumonia. In addition, combina-
tion therapy did not show a benefit with regard to decreasing 
superinfection rates or the emergence of resistant pathogens 
[6, 194–197]. In a meta-analysis of eight randomised, con-
trolled studies on patients with different infections β-lactam/
aminoglycoside combination therapy did not impact favour-
ably on the emergence of resistance. Fewer superinfec-
tions were observed with monotherapy (OR 0.62; 95 % CI, 
0.42–0.93) than with combination therapy [198]. Further-
more, combination with aminoglycosides is associated with a 
higher incidence of nephro- and ototoxicity [199–201]. Thus, 
de-escalation to monotherapy is recommended based on type 
of infection and microbial culture results [202]. Combination 
therapy is only recommended for selected indications.
Observational studies on general wards and intensive 
care units show that 20–60 % antibiotic treatments could be 
adjusted based on microbial findings alone [193, 203–205]. 
Pharmacists and infectious diseases physicians assessed 
combination therapy as being unnecessary in 50 % of cases, 
measurable effects of de-escalation were reduced length 
of hospital stay and high-cost savings [206–208]. In an 
intervention, a computer programme identified combina-
tion antibiotic therapy across the hospital, which was then 
evaluated by a pharmacist or infectious diseases physician 
for adequacy. 98 % of combination therapy was found to be 
redundant. The implementation led to considerable net sav-
ings [209].
The effect of de-escalation, or treatment adjustment 
based on microbial culture results and/or clinical criteria 
was well demonstrated in at least one multicenter clini-
cal study of patients in intensive care. Patients suspected 
of having developed ventilator-associated pneumonia 
receiving treatment in 31 French intensive care units were 
switched to targeted treatment based on culture and sen-
sitivity results of pathogens obtained by bronchoalveolar 
lavage or endotracheal aspiration. Patients who received 
treatment based on bronchoalveolar lavage culture results 
had significantly more antibiotic-free days (5 vs 2), sig-
nificant 10 % lower mortality at day 14 and decreased 
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sepsis-related organ failure at day 3 and 7 [100, 103]. The 
authors related this to the fact that invasive bronchoscopy 
allows to differentiate better between pulmonary infection 
and colonisation, and that antibiotic treatment can be dis-
continued earlier given negative cultures from bronchoal-
veolar lavage. In a randomised controlled trial conducted 
in an intensive care unit in North America, the course of 
antibiotic therapy of pneumonia was shortened by 2 days, 
based on clinical criteria, without negative impact on mor-
tality [210]. Numerous other investigations confirm these 
observations and show that adjusting therapy is usually 
possible after 48–72 h [211–214].
3.1.2 Duration of treatment  
double-blind study of patients with ventilator-associated 
pneumonia undertaken in 51 French intensive care units. 
It was demonstrated that 8-day treatment had no disad-
vantage for these patients as compared to 15 days. Shorter 
treatment duration was associated with emergence of 
fewer multidrug-resistant pathogens (−20 %) [101, 102]. 
These findings and the results of other similar studies have 
had a decisive influence on the assessment and conclusions 
reached in recent meta-analyses [222, 223]. Other good 
scientific studies on urinary tract infection show similar 
results [224]. When implementing ABS programmes, treat-
ment orders for patients with community-acquired pneu-
monia should for instance be linked to a note “no longer 
than 5–7 days” to remind users to undertake an individ-
ual clinical reassessment of further treatment beyond this 
point in time. This question can also be addressed in pro-
active audits of antiinfective drug use [225, 226].
Biomarkers can also be useful to guide duration of ther-
apy. Corresponding studies are available on use of Procal-
citonin particularly in the management of patients with res-
piratory tract infections, whereby treatment duration in the 
control arm does not correspond in some cases to today’s 
standards. Various systematic reviews and meta-analyses are 
available on Procalcitonin [227, 228]. Determination of Pro-
calcitonin levels can influence the density of antibiotic treat-
ment in intensive care units: in a prospective study antibiotic 
treatment was reduced by 23 %, in other studies this effect 
remains, whereby the cost-effectiveness is unclear and there 
seems to be no impact on mortality [229–235].
Numerous studies have aimed to improve adherence to 
guidelines on perioperative antibiotic prophylaxis, espe-
cially with regard to duration. Training programmes, local 
guidelines and checklists in the operating room with and 
without use of computer-based information technology 
were most often applied. For various reasons the results 
are not always satisfactory and comparable, depending on 
intervention and speciality field [128, 129, 158, 188, 236–
242]. Some examples of successful outcome are the signifi-
cant reduction of treatment duration from 2.4 to 1.6 days 
(Japan), the 15 % reduction in the amount of antibiotics 
prescribed for perioperative antibiotic prophylaxis (Ger-
many), the increase in the proportion of guideline-adherent 
prophylaxis of no longer than 24 h duration from 3 to 66 % 
(Taiwan) and the reduction of prolonged prophylaxis >24 h 
from 21 to 8 % (Netherlands). A time-series analysis of 13 
hospitals in the Netherlands demonstrated convincingly 
that targeted training programmes result in a decrease of 
perioperative antimicrobial drug use from 121 to 99 DDD 
(defined daily doses)/100 procedures, and in a cost reduc-
tion of 25 % per procedure [188]. If available, electronic 
prescribing systems can be used for automatic stop orders 
to reduce the proportion of patients with prolonged prophy-
laxis. In a US study, by computer-based order intervention, 
The guideline development group recommends:
It is possible to shorten the duration of antiinfective 
treatment for many indications (e.g. perioperative anti-
biotic prophylaxis) and this is recommended wherever 
backed by good studies and evidence. The ABS team 
should utilise local guidelines and antiinfective point-
of-care chart reviews to draw attention to the excessive 
duration of treatment frequently encountered in practice. 
The ABS team should define the duration of treatment 
recommended as a rule, since this is expected to impact 
substantially on antiinfective drug use, side effects and 
costs (A). Use of biomarkers such as Procalcitonin may 
be useful for controlling the duration of treatment in 
cases where there is clinical uncertainty. As a result, the 
number of days of antibiotic therapy can be reduced and 
under certain circumstances costs can be cut (C).
A frequently encountered problem in regard to anti-
biotic therapy is the duration of antimicrobial treatment 
often being too long. Large-scale studies in the USA, in 
European countries and elsewhere have repeatedly dem-
onstrated prolonged duration of perioperative antibiotic 
prophylaxis—in 50 % or more cases perioperative antibi-
otic prophylaxis was administered for longer than 24 h [85, 
86, 215]. This unnecessarily increases selective pressure 
for resistance to emerge [102, 216–219].
German recommendations with S3 Guideline level, e.g. 
on community-acquired and hospital-acquired pneumo-
nia or uncomplicated community-acquired urinary tract 
infections, give explicit, evidence-based recommenda-
tions on duration of treatment (http://www.awmf.org). 
The results of the studies on which the recommendations 
on pneumonia are based demonstrate convincingly that 
the mean duration of treatment can be reduced without 
negative impact on clinical outcome and mortality [102, 
220, 221]. An important trial is a prospective randomised 
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the proportion of patients who had prophylaxis discontin-
ued in the appropriate time frame increased by 17 %, com-
pared to no change without intervention [243].
3.1.3 Parenteral‑to‑oral conversion 
patients could be switched to oral antibiotics at day 3, and 
a further 20 % between day 4 and 7. Similar experience 
was made in a series of other observational studies [39, 76, 
111, 256, 257]. Safety was also investigated with respect 
to study endpoint hospital readmission [258, 259]. 
With the exception of endocarditis and meningitis, 
timely switch to oral antibiotic administration can also be 
reasonable for pyelonephritis, for skin and soft tissue infec-
tions, febrile neutropenia, infantile osteomyelitis/purulent 
arthritis [252, 260–267]. Systematic review of good clini-
cal studies partially performed in Europe shows that switch 
to oral antibiotic administration for another 7–11 days is 
already possible at day 3 of parenteral therapy for treat-
ment of infantile pyelonephritis without a higher incidence 
of renal damage or other complications [268–271]. Other 
studies have documented substantial cost savings from 
early shift to oral antibiotics and as a consequence ear-
lier discharge from hospital [64, 272–274]. Some of these 
investigations were conducted by hospital pharmacists 
themselves [39, 275]. Prospective observational studies 
investigating early switch to oral antibiotics have demon-
strated that sustainability can be achieved by checklists, 
clinical pathways defining criteria for early conversion to 
oral therapy and its implementation supported by hospital 
pharmacists [258, 276–280].
3.1.4 Dose optimisation  
The guideline development group recommends:
If sufficient bioavailability is assured, and if the 
patient’s condition allows, therapy should be switched 
from parenteral to oral antibiotic application (A). This 
measure reduces the length of hospital stay and the risk 
of line-related adverse events. Furthermore, it leads to a 
reduction in the total cost of treatment. Implementation 
of programmes allowing parenteral-to-oral conversion 
of antimicrobial agents at the institutional level ought to 
be facilitated by developing clinical criteria and through 
explicit designation in institutional guidelines or clinical 
pathways (B).
Critically ill patients suffering from an infection, ini-
tially receive parenteral antibiotics. Stabilised patients as 
well as patients with a less serious illness can be given oral 
agents with good bioavailability as long as there are no 
contraindications (e.g. disorders of gastrointestinal resorp-
tion or dysphagia) (Table 6). Conversion to oral adminis-
tration has numerous advantages. Mobility is improved, 
patients can be discharged earlier, the risk of adverse line-
related events is smaller, and the amount of nursing time 
required is usually reduced. Switch to oral antibiotics has 
been well investigated for certain indications, and recom-
mendations are made in many guidelines, e.g. the German 
guideline for treatment of community-acquired pneumonia 
[6, 244–246]. Safety of switch to oral administration was 
evaluated in at least one meta-analysis and several partly 
multi-centre randomised controlled clinical trials. It was 
demonstrated, that duration of parenteral treatment and 
length of stay can be reduced by approximately 2–3 days 
without increasing mortality [61, 247–255]. In a pro-
spective quasi-experimental observational study involv-
ing around 200 pneumonia patients, almost 70 % of the 
The guideline development group recommends:
Adequate adjustment and optimisation of the dose 
and dosing interval is essential for effective, safe and 
responsible administration of antiinfective therapy, and 
an important part of ABS programmes. Besides indi-
vidual patient factors, optimal dosing of antiinfectives 
should take into account, the nature and severity of ill-
ness, the causative microorganism, concomitant medica-
tions, as well as the pharmacokinetics and pharmacody-
namics of the agents prescribed. Strategies to optimise 
dosing in ABS programmes should include assessment 
of organ function for drug dose adjustment in order to 
avoid adverse drug events and unwanted drug interac-
tions (A).
Furthermore, optimising the dosing interval and dura-
tion of infusion is recommended in particular in criti-
cally ill patients, best by employing a therapeutic drug 
monitoring (TDM) scheme; appropriate consented local 
institutional guidelines should be available and up to 
date (B).
Evaluation of ABS programmes showed that one-third 
of all interventions was in regard to dose optimisation of 
Table 6  Substances with good-to-excellent bioavailability









antimicrobial treatment. This was demonstrated in many 
retrospective studies which provided evidence of inappro-
priate choice of agent and inadequate dosing [281–287]. As 
with all medication, antiinfective dosing requires individual 
review and adjustment. If need be, dose and dosing inter-
val must be adjusted, whereby age, weight, gender, hepatic 
and renal function, underlying and concomitant disease as 
well as co-medication must be considered. Dosing is largely 
determined by pathogen susceptibility, the location and 
severity of infection [288]. Dose optimisation programmes 
have been implemented by pharmacists and infectious dis-
eases physicians with similar success and can also be cost 
effective [37, 289–297].
Pharmacokinetic and pharmacodynamic (PK/PD) prop-
erties are important to achieve optimal antiinfective dose 
levels [298, 299]. Emergence of resistance can be pro-
moted by using incorrect, low dosages of antibiotics with 
low-resistance barrier [216]. Therefore, strategies to avoid 
incorrect drug dosage or suboptimal dispensing appear use-
ful, at least in critical areas such as intensive care units, 
despite uncertain evidence for a clinical benefit [101, 300–
305]. Important strategies are optimisation of dosing inter-
vals (e.g. higher concentrations of aminoglycoside with an 
extended dosing interval) [306] and prolonged infusions 
of beta-lactams especially in presence of critical illness or 
multidrug-resistant microorganisms [307]. In this setting, 
therapeutic drug monitoring (TDM) can improve antibiotic 
dosing [308–310].
By using TDM, the proportion of patients with serum 
piperacillin concentrations within therapeutic range 
increased from 50 to 75 % in a 30-bed intensive care unit in 
a French teaching hospital [311]. A much cited, multi-centre 
study from the Netherlands conducted in medical and sur-
gical wards of four hospitals was able to show that active 
TDM-guided dosing of aminoglycosides and dosing recom-
mendations by clinical pharmacists can significantly shorten 
length of stay by approximately 6 days and reduce incidence 
of nephrotoxicity from 13 to 3 %. A highly detailed cost-
effectiveness analysis showed overall cost savings of 30 % 
[312]. Similar results were reported from France [313, 314]. 
The benefits of single-dose aminoglycoside administration 
compared to multiple-dose and extended-interval aminogly-
coside dosage regimens can be utilised to minimise nephro-
toxicity in children [38, 315, 316].
PK/PD analyses show that with beta-lactam antibiot-
ics the duration of time that drug levels exceed the MIC of 
the pathogen at the site of infection is important to achieve 
better treatment outcomes (time-dependent killing). Beta-
lactams with short half lives (<2 h) should actually be 
given as extended or continuous infusion, which requires 
drug stability at room temperature [317, 318]. An older 
meta-analysis [319, 320] suggests that clinical outcome in 
continuous intravenous infusion of suitable beta-lactams 
seems to be superior to intermittent infusion of the same 
daily dose. More recent systematic reviews investigat-
ing continuous infusion have not confirmed superiority 
[310, 321], whereby different daily doses were compared, 
though in certain studies very good effects were observed. 
McKinnon et al. [322] for instance showed in a prospective 
randomised investigation in critically ill patients with bac-
teremia that continuous infusion ceftazidime or cefepime 
is superior to intermittent short-term regimen: clinical 
improvement and mortality differed significantly. In a ran-
domised study of bacterial meningitis, where cefotaxime 
was administered in the first 24 h by continuous infusion 
versus intermittent bolus, a benefit was seen in favour of 
continuous infusion in terms of lower mortality [323]. 
Treatment success can be achieved by the drug concentra-
tion being 40–60 % of the time in the 2- to 4-fold range 
of the MIC. Drug concentrations remaining above the 
MIC 100 % of the time is not necessary. An intermittent 
dosing strategy with longer duration of infusion can thus 
suffice to guarantee optimal outcome [324]. A retrospec-
tive multicenter study showed that increasing length of 
infusion (4 h) gives better clinical results for intermittent 
dosing of piperacillin/tazobactam. Mortality was reduced 
from 18 to 10 % (p = 0.02) [325]. A similar (before and 
after) observational study (larger number of cases) with 
cefepime, piperacillin/tazobactam and meropenem could 
not reproduce these positive results [326]. In yet a further 
prospective investigation conducted across Australia and 
Hongkong with 2 × 30 patients (in addition to piperacil-
lin/tazobactam, ticarcillin/clavulanate and meropenem 
were permitted), PK parameters were defined as primary 
endpoint. The clinical results are of interest nevertheless: 
clinical cure was observed in 70 vs 43 % (continuous vs. 
bolus) (p < 0.01), and survival in the two arms was 90 vs 
80 % [327]. In a Czech study, 2 × 120 patients (inten-
sive care, medium APACHE-II-Score >20, high incidence 
of Klebsiella infection) were randomised in continuous 
infusion group and bolus group. A high loading dose was 
given in both arms. Clinical cure (83 vs. 75 %, p = 0.18) 
and microbiological success rate (91 vs. 78 %, p = 0.02) 
were better with continuous infusion. However, a very 
high loading dose of meropenem was given in both arms 
(4 × 1 g over 6 h vs. 3 × 2 g over 30 min) [328]. Addi-
tional findings in the continuous infusion group were 
shorter ICU stay (10 vs. 12 days), shorter duration of ther-
apy (7 vs. 8 days) and (as to be expected from the study 
design) lower total dose of meropenem. Concerning mor-
tality, no significant statistical difference (hospital, ITT 
population) was detected (17 vs. 23 %).
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3.1.5 Scheduled switch of antimicrobials two strategies with heterogenous use of cephalosporins, 
penicillins, carbapenems and fluoroquinolones, cycling 
led to a significant increase in resistant nosocomial pneu-
monia pathogens [345]. Thus, with respect to antimicro-
bial classes, attention should be paid to use of balanced, 
guideline-adherent therapy. Above all, excessive use of 
cephalosporins and fluoroquinolones should be avoided. 
If surveillance data of cephalosporins and fluoroqui-
nolones point to excessive consumption, a strategic class 
switch in preference of penicillins should be undertaken. 
There are several new publications on this topic. Follow-
ing an educational campaign and subsequent introduction 
of restrictions, the policy “Reduction of routine use of 
ceftriaxone and ciprofloxacin in favour of aminopenicil-
lins” was successfully implemented in a Scottish hospital. 
The endpoints observed were change in the incidence of 
hospital-acquired MRSA and ESBL-positive infections 
(without special screening) as well as C. difficile rates. 
As result of the new policy, consumption of ceftriaxone 
reduced by 95 % and that of ciprofloxacin by 73 % (com-
parison of the first and final 6 months of the study). At 
the same time, hospital-acquisition rates for C. difficile 
reduced by 77 %, MRSA by 25 % and ESBL cases by 
17 %. The intervention had a sustained effect (up to 3 
years later) [346]. Other observational studies on strategic 
antimicrobial substitution of cephalosporins in favour of 
penicillins conducted in China, Greece and India seem to 
confirm a decline in ESBL cases, however, cannot prove it 
[347–350].
3.2  Special rules for communication of microbiology 
results
The guideline development group recommends:
So-called “Cycling” programmes, which involve peri-
odically removing a specific antimicrobial drug or an 
antimicrobial drug class as the standard recommended 
therapy and later reintroducing it (periodic scheduled 
rotation), are not suitable as a strategy to reverse critical 
emergence of resistance or to control nosocomial out-
breaks with multiple resistant pathogens and, as such, 
should not be used as a strategy to do so (A).
Strategic rotation of specific antimicrobial drugs or 
antimicrobial drug classes ought to be undertaken to 
limit the selective pressure and to achieve a reduction of 
infectious microorganisms or microorganisms display-
ing specific resistance properties for a certain time (B). 
There is evidence to suggest that a balanced use of dif-
ferent antimicrobial drugs or antimicrobial drug classes 
(so-called “mixing”) can minimise the emergence of 
resistance. In both cases, routine surveillance of antimi-
crobial drug use and resistance should be performed (A).
Repeated rotation of different antimicrobials or anti-
microbial classes (e.g. cephalosporins, fluoroquinolones, 
penicillins, carbapenems) for empiric therapy of acute 
infection within an institution or specific unit—so-called 
“Cycling”—was designed to limit selective pressure and 
thus prevent development of resistance toward frequently 
prescribed antimicrobials/antimicrobial classes. Published 
experience with cycling strategies, mainly on aminoglyco-
sides, is a few decades old, and, in view of the minor share 
of aminoglycosides used, of little interest in clinical rou-
tine today. Neither are the studies consistently successful 
in showing a detectable effect in minimising resistance [6, 
329, 330]. In many cases, implementation was problem-
atic, with up to 50 % of the patients in cycling programmes 
receiving “off cycle” antimicrobials, i.e. not receiving per 
protocol antimicrobial treatment [6].
More recent studies on cycling of broad-spectrum 
beta-lactams show little improvement in methodology 
or results [331–337]. Neither do mathematical models 
of antimicrobial cycling demonstrate benefit in respect 
of avoiding resistance. Mathematical modelling suggests 
that antibiotic cycling strategies, prompting simultaneous 
diversity of antimicrobials/antimicrobial classes, perform 
better than temporary dominance of a single antimicrobial 
agent/antimicrobial class [338–340]. Several clinical tri-
als confirm this concept [341–344]. Within the scope of a 
Spanish prospective intervention study on ventilator-asso-
ciated pneumonia in an interdisciplinary intensive care 
unit, it could indeed be demonstrated that, compared with 
The guideline development group recommends:
The quality of microbiology diagnostics depends cru-
cially on compliance with guidelines on procedures in 
the preanalytical phase. Expert consensus recommends 
that any deviations from protocol ought to be reported 
and the reasons for rejecting the samples stated (B).
Technical progress and up-to-date molecular diag-
nostic methods for rapid pathogen detection should be 
used if they improve the quality of care and/or substan-
tially improve identification and epidemiologic investi-
gation of local outbreaks (A).
Positive blood culture findings, interim microscopic 
findings, results of rapid testing and rapid susceptibil-
ity testing should be delivered promptly to the attending 
physician (A).
Antibiograms ought to adhere to local guidelines 
with respect to antimicrobial use and diagnostic find-
ings, be presented selectively in agreement with the 
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ABS team, and, if need be, include relevant interpreta-
tive comments. This procedure aids selection of a tar-
geted, guideline-based antibiotic therapy (B).
The microbiology laboratory is responsible for the 
timely identification of trends in antimicrobial resist-
ance and prompt communication of observations to the 
ABS team and the physicians responsible for infection 
control (A). This way, the clinical and epidemiologi-
cal significance of the observations can be defined at an 
early stage.
Automated MIC-based antibiograms and integration of 
molecular diagnostic assays such as PCR, PNA-FISH or 
MALDI-TOF into microbiology diagnostic can shorten 
time to pathogen identification and reporting of results 
[358]. Several prospective, randomised clinical stud-
ies on diagnostic of blood cultures and respiratory sam-
ples in pneumonia have shown that more rapid detection 
of pathogens by a few days resulted in earlier targeted 
antibiotic therapy. Thus, duration of empirical therapy, 
duration of ventilation and length of hospital stay were 
reduced by a few days and mortality decreased variably 
[36, 359–366]. More recent prospective investigations 
on use of rapid Legionella urinary antigen test in pneu-
monia patients have shown that it is a useful tool with 
which targeted antimicrobial treatment can be provided 
more frequently. This was less conclusively demonstrated 
for pneumococcal antigen in urine [367, 368]. How-
ever, carefully developed and implemented algorithms 
are necessary to maintain the potential benefit. At least 
two controlled before-and-after studies have shown that 
antibiotic therapy is only modified and adjusted to micro-
biological findings, i.e. blood culture results, if these are 
communicated personally to the treating physician or the 
culture results are documented in the patient’s medical 
chart [369–371].
The guideline development group recommends the use 
of selective reporting of susceptibility testing results with 
respect to choice and number of antimicrobial agents 
depending on pathogen, local susceptibility data and 
existing therapy guidelines, with the objective of support-
ing guideline-adherent antibiotic therapy [1, 6, 372]. Two 
methodologically different interrupted time-series analy-
ses indicate that selective antibiotic susceptibility report-
ing can influence prescribing behaviour [373, 374]. Addi-
tional reporting, providing information on major resistance 
mechanisms, on contamination or colonisation according 
to pathogen and pathogen quantity, or information on diag-
nostic and therapeutic guidelines can support ABS meas-
ures. However, the effect of the mode of reporting microbi-
ology results on prescribing behaviour is not well studied.
In case of unprecedented or critical levels of bacterial 
resistance, the microbiology laboratory should identify the 
cause by molecular biological methods as well as charac-
terisation of clonal variants by typing, in particular during 
outbreaks and in this case especially with the assistance 
of reference laboratories. Depending on test results, tar-
geted ABS strategies should be seized by the ABS team in 
accordance with appropriate hygiene interventions, imple-
mented by the infection control team.
The microbiology laboratory plays a crucial role in 
achieving the objectives of an antimicrobial stewardship 
programme by providing timely identification of relevant 
pathogens, selective antibiograms and active communica-
tion of diagnostic results and their interpretation, including 
interim reports. Microbiology diagnostics and susceptibil-
ity testing and reporting should be based on latest national 
[e.g. quality standards of microbiology and infectious dis-
eases (MiQ) for Gemany] and international quality stand-
ards (http://www.eucast.org), should address the specific 
requirements of the requesting physician and live up to the 
hospital’s obligation to provide medical care. A meaningful 
microbiological diagnostic requires optimal sample quality, 
storage, and timely transport of samples to the laboratory. 
The transport time of urine samples stored at room tem-
perature should not exceed 2 h, since delays in transport of 
samples to the laboratory may increase pathogen growth 
and produce false-positive test results [351, 352]. Samples 
that deviate from guideline-adherent pre-analytics ought to 
be reported or ought to lead to the implementation of rejec-
tion criteria. Criteria ought to be defined for all common 
samples—e.g. sputum, urine, stool and swabs—to avoid 
unnecessary antimicrobial therapy. It is for instance recom-
mended that purulent sputum with more than 25 squamous 
epithelial cells per field ought not to be further screened; 
rather, findings ought to be reported and the sputum sam-
ple discarded [353–355]. Microbiological diagnostic of 
good-quality sputum samples can provide valuable infor-
mation on the pathogen involved. Older studies investigat-
ing patients with pneumonia were able to show that high-
quality sputum samples resulted in targeted antimicrobial 
monotherapy more often [356, 357] than inadequate spu-
tum or no sputum culture. Reporting is also of importance 
on samples from non-implanted foreign bodies (drains, 
urinary catheters, venous catheters, tracheal cannula, 
wound sponge, etc.) or where low sample volume impairs 
sensitivity.
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3.3  Special rules for management of patients 
with multidrug‑resistant microorganisms and C. 
difficile
until restriction of cephalosporins, macrolides and clinda-
mycin was imposed 6 months later that the incidence of C. 
difficile-associated disease decreased by 60 %. Utilisation 
of broad-spectrum penicillin subsequently increased com-
pensatorily without repeated emergence of the epidemic C. 
difficile strain [73]. An investigation carried out over several 
years in a geriatric unit showed that the incidence of C. dif‑
ficile diarrhoea was strongly associated with the density of 
cefotaxime use [378]. More recent time-series analyses over 
a period of 12–24 months confirm that substituting cepha-
losporins and fluoroquinolones for penicillins can lead to a 
decrease in the incidence of C. difficile-associated disease. 
Cephalosporin and fluoroquinolone use decreased consider-
ably by more than 22–50 % [144, 146].
It is possible to influence the incidence of ESBL-pos-
itive isolates by implementing strategies to control anti-
biotic consumption. Various methodologically different 
but demanding studies on restriction of cephalosporin 
use showed a decrease in the rate of infection and colo-
nisation with ESBL-producing microorganisms [349, 350, 
379–381]. However, in respect to sustained minimisation 
of resistance, the effects of a policy for targeted restric-
tion of antimicrobials are less conclusive [124, 382] and 
sometimes even contradictory [383–387]. Particularly, 
unplanned increased consumption of alternative agents, 
in setting of restriction, can rapidly impact negatively 
on the resistance situation [135, 388, 389]. The effect of 
restriction of third-generation cephalosporins, vancomy-
cin and/or fluoroquinolones varied in regard to VRE and 
MRSA [117, 383–385, 390, 391]. For instance, a short-
term effect of restriction of vancomycin and cephalospor-
ins on gastrointestinal colonisation with VRE (decrease 
from 47 to 15 %) was observed [392]. According to long-
term observations, VRE eventually increased again [393]. 
Infection control practices seem to have a stronger sus-
tained effect in this regard, and ABS strategies alone may 
not suffice.
In case of high incidence of multidrug-resistant micro-
organisms and cumulative outbreaks, appropriate recom-
mendations on diagnostic tests, evaluation of findings and 
treatment, as well as infection control management must be 
coordinated immediately and disseminated locally. There is 
generally great uncertainty about optimal treatment [394]. 
In certain circumstances, use of unconventional antimicro-
bials or of conventional antimicrobials in unusual dose and 
combination may become necessary. In this situation, it is 
indispensible for the ABS team to draft appropriate guid-
ance and recommendations in collaboration with the micro-
biology laboratory, to allow optimal treatment outcome and 
not to promote further spread of multidrug-resistant micro-
organisms through inadequate antibiotic use.
The guideline development group recommends:
ABS strategies should be used to prevent infection with 
C. difficile (A). Restricting use of certain antimicrobial 
drugs or substitution of antimicrobial drug classes (e.g. 
penicillin for cephalosporins or fluoroquinolones) can 
considerably reduce the incidence of C. difficile infec-
tion. Infection prevention and control strategies are fre-
quently also applied at the same time; however, they 
have less impact on the C. difficile incidence than in the 
epidemiology of MRSA or VRE.
Targeted ABS strategies are to varying degrees also 
effective in reducing multidrug resistant Gram-negative 
bacteria, particularly ESBL-producing microorganisms, 
MRSA and VRE, and ought to be specifically applied 
here too (B). In case of high prevalence of multidrug 
resistant microorganisms, recommendations on diag-
nostic tests, evaluation of findings and treatment, as well 
as infection control management should be coordinated 
immediately and disseminated locally (A).
Routine surveillance of antimicrobial consumption 
and antimicrobial susceptibility data should be per-
formed (A) to avoid indiscriminate compensatory use 
of other antimicrobial drug classes, since this can pro-
mote the unintentional and uncontrolled emergence of 
resistance.
The importance of appropriate ABS strategies for the 
management of patients with multidrug-resistant microor-
ganisms and C. difficile is well documented in several sys-
tematic reviews and corresponding studies especially for 
C. difficile [2, 8, 22, 25, 375]. Pretreatment especially with 
third-generation cephalosporins and fluoroquinolones pre-
sents a risk factor for C. difficile infection, as well as for the 
increase in ESBL-producing Gram-negative microorgan-
isms, MRSA and VRE [376, 377].
In before-and-after studies restriction of some types of 
antimicrobials, particularly third-generation cephalosporin 
and fluoroquinolones, but also macrolides and clindamy-
cin, resulted in a 50 % or higher reduction in the incidence 
of C. difficile-associated disease. Frequently, interventions 
were accompanied by general infection control strategies. 
However, even in controlling outbreaks, infection con-
trol practices do not always appear to be sufficiently suc-
cessful, as shown by the data collected retrospectively in 
a methodologically robust time-series analysis. It was not 
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3.4  Computerised information technology Besides automated electronic alerts/short consultations 
and computerised decision support systems, in future, elec-
tronic prescribing systems, i.e. patient-based computer 
physician order entry systems (CPOE) with and without 
approval and reminder/alert functions will be particularly 
important for interventional ABS activities. As far as pre-
scribing quality is concerned, these systems offer many 
advantages over paper-based medication orders with regard 
to legibility, completeness, fast delivery of information and 
possibly to approval or reminder/alert functions [402]; how-
ever, they are not as yet standard practice in German-speak-
ing countries. By using CPOE systems, the rate of medica-
tion ordering errors can be reduced considerably (dosing, 
interactions, allergies) [403–407]. On the other hand, the 
extent to which these systems influence resistance or clini-
cal outcomes and mortality is inconclusive [408–413]. In 
addition, CPOE systems could facilitate audits of antimicro-
bial prescribing through timely provision of patient-related, 
cross-unit and cross-departmental antimicrobial prescribing 
data [414, 415]. In a randomised controlled trial conducted 
in the USA, an ABS team [infectious diseases physician 
(50 % FTE), clinical pharmacist (80 % FTE)] reviewed 
antibiotic prescribing based on a list of alerts generated by 
an electronic decision support system. Among others, the 
following selection criteria were used: intravenous anti-
microbial application in spite of good oral bioavailability, 
unnecessary combination therapy, and antibiogram discord-
ant therapy. Compared with the control arm, USD 38 were 
saved per day per patient (around 16 % of total antibiotic 
costs) and 1 h of work a day with automated system alerts 
[416, 417]. A reduction in rates of antimicrobial use can be 
achieved by integrating an antimicrobial approval system 
into electronic prescribing [75, 243, 408, 409]. Web-based 
reviews of guideline-adherent prescribing of third-genera-
tion cephalosporins resulted in a significant 50 % reduction 
that was sustained over 15 months [75]. In another study, 
vancomycin use required an indication (by drop-down menu 
or free text) at initial electronic ordering and after 72 h. 
Treatment was stopped automatically if no indication was 
entered both times. As a result, initial vancomycin orders 
per physician were reduced significantly by 29 %, and 36 % 
fewer renewal orders were written after 72 h. The amount of 
days of vancomycin therapy decreased by 36 %. However, 
no information was provided on clinical outcome [418]. 
Electronic prescribing systems can contribute to reduce anti-
biotic expenses, if information on antibiotic cost/hospital 
day is provided while the order is placed [419]. This seems 
to be more effective than automated feedback to prescribers 
on antibiotic expenditure in comparison to others [420].
Electronic documentation of the timing of periopera-
tive antibiotic prophylaxis with provider-specific feedback 
(confidentially to the anaesthetist) on the rate of prophy-
laxis given too early or too late appeared to be effective. At 
The guideline development group recommends:
The ABS team should be supported by novel informa-
tion and communication technology in the implementa-
tion of ABS programmes. Local treatment guidelines, 
the antiinfective formulary, and other ABS documents 
should be available electronically (A).
Electronic prescribing tools with and without linkage 
to electronic preauthorisation solutions to ABS docu-
ments or to active communication of information using 
computerised reminders to the prescriber should be used 
to improve the use of antiinfectives in the interests of 
patient safety (A). They ought to be used to reduce con-
sumption and/or costs (B).
Computerised decision support systems that are inte-
grated into the hospital’s internal information system 
can, by utilising electronic medical records, help evalu-
ate and optimise the indication for antiinfective therapy, 
drug selection and dosing (C).
To implement computerised ABS measures, the ABS 
team must have hospital-wide access rights to electronic 
medical records (with due respect to data protection).
The ABS team should be supported by novel computer-
based information and communication technology through 
the provision of hospital-wide availability of ABS docu-
ments (antiinfective formularies, guidelines, treatment 
pathways). Development and application of electronic com-
puterised decision support systems (CDSS) is to be encour-
aged. To utilise these systems optimally, it is useful to link 
them to an electronic patient record/chart or/and a patient-
based computer physician order entry system (CPOE). In 
spite of the tremendous advances that have been made in 
the development of these systems in the hospital sector, 
availability varies in German and Austrian hospitals. Soft-
ware designed specifically for ABS purposes hardly exists 
at all. Systematic reviews evaluating the impact of CDSSs 
specifically in the field of ABS (studies to 2007) found 
them to be of limited benefit [395, 396].
Electronic hospital information systems are used to vary-
ing extent in most hospitals in Germany. The system gives 
the treating physician access to patient-related and treat-
ment-relevant data. In the interests of patient safety, and 
taking account of data protection, the ABS team should 
also have access to these data (antiinfectives, and microbio-
logical laboratory results). Furthermore, electronic hospital-
wide surveillance data on pathogens and antiinfective con-
sumption should be available to the ABS team at all times. 
The ABS team should receive support on use and layout of 
computerised information systems from experts [397–401].
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the time the intervention was initiated 69 % of the patients 
received antibiotics within 60 min of incision, and 92 % 
a year later [421]. Similar good-to-very good results were 
reported for the use of so-called electronic “Real-time 
Alerts” in improving timing of perioperative prophylaxis 
(>99 % of perioperative prophylaxis in one study). An 
electronic alert system was implemented after 4 h operat-
ing time to remind surgical teams to redose perioperative 
prophylactic antibiotics. The intervention was effective: 
68 % of patients with cardiac surgery in the reminder group 
received intraoperative redosing versus only 40 % in the 
control group. The rate of surgical site infection was simi-
lar in both groups (4 und 6 %), but lower than in the pre-
study period (10 %) [422,  423].
Several studies on electronic expert systems were con-
ducted in a hospital in Salt Lake City (1986–2001). Imple-
mentation in many German hospitals, however, is difficult 
on account of inadequate technical prerequisites. These sys-
tems provide clinical decision support in the form of detailed 
therapy recommendations and alerts based on interlinked 
data such as allergies, laboratory results, microbiological 
findings, etc. Studies on this programme showed a significant 
reduction in the number of antibiotics prescribed, duration of 
treatment, costs, and adverse drug events [237, 424–431]. A 
comprehensive computerised system consisting of an anti-
microbial guideline and approval system in regard to reserve 
antibiotics also proved highly effective in an Australian hos-
pital. It facilitated turning around a trend towards greater use 
of reserve antibiotics and resulted in increasing conform-
ity with guideline-recommended therapies [432]. Effects 
were less strong in other studies. In a European multi-centre 
study (incl. Denmark, Italy, Germany) a computerised deci-
sion support system that looked at local susceptibility data, 
showed a rate of “appropriate” empirical antibiotic treat-
ment of 73 %, which was only negligibly better than that of 
the control group of 64 % [433]. A reduction of just under 
11 % in antibiotic consumption was achieved in an Austral-
ian intensive care unit, while the proportion of inappropriate 
antimicrobial use declined by only 10 % [412].
Appendix
See Tables 7, 8 (Sect. 2.2.4). 
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Table 7  ABS structure indicators
to 1. Requirements
Personnel/team/mandate/infrastructure
• Multidisciplinary ABS team is appointed and authorized by the hospital management and is 
headed by an infectious diseases physician (or physician trained in ABS) plus pharmacist
• ABS team is represented in the Therapeutics and Drugs committee
• At least 2 (recorded) ABS team meetings per year
• ABS strategic report includes quantitative objectives with selected quality indicators
• In-house preanalytical requirements for microbiologic samples, including rejection criteria, have 
been defined
Antimicrobial drug use surveillance/data
• Antimicrobial consumption data (in the form of DDD/RDD or PDD per 100 patient days or per 
patient) available at least once per year for several clinical divisions (departmental and/or 
medical vs surgical divisions and/or general ward vs intensive care unit) and for the most 
important antiinfective drug classes and total consumption 
• Rate of oral vs. parenteral dispensed or prescribed daily doses (% DDD/RDD or PDD) of the 
most important and relevant drugs available at least once per year for several clinical divisions
(departmental and/or medical vs surgical divisions and/or general ward vs intensive care unit) 
Infection and resistance surveillance/data
• Selected resistance rates and corresponding incidence figures (for clinical isolates) available at 
least once per year hospital-wide or for at least one clinical division
• Incidence figures for Clostridium difficile-associated diarrhea available at least once per year for 
several clinical division (departmental and/or general ward vs intensive care unit) 
• Hospital-wide incidence figures for nosocomial sepsis/bacteremia available at least once per year
to 2. ABS core strategies
A ntiinfective formulary and local consensus treatment guidelines
• In-house list of antiinfectives (formulary) is available and up to date (not older than 2 years)
• Prescription of restricted/alert antiinfectives from a defined list is individualized (specific patients) 
and must be approved
• Written, locally consented practice guidelines for empiric therapy,detailing the most important 
indications and infectious diseases are available and up to date (not older than 2 years)
• Written, locally consented practice guidelines for surgical prophylaxis are available and up to 
date (not older than 2 years)
• Written recommendation for parenteral-to-oral switch antimicrobial therapy (criteria & agents) are 
available and up to date (not older than 2 years)
Information, training and education
• Educational sessions about local consented practice guidelines (tailored to clinical divisions 
needs and/or ward type) organized by ABS team members or ABS representatives from clinical 
divisions at least every other year
• Internal or external ABS-relevant continuing professional education offered for at least 10 % of
medical staff who are not ABS representatives with at least 4 ABS relevant CME credits per year
• ABS-relevant continuing professional education offered for ABS team members and ABS 
representatives from clinical divisions with at least 8 ABS-relevant CME credits per year
Audits and use of indicators
• Regular ward rounds by ABS team members with attending physicians in at least three clinical 
services/departments, at least three times each per year
to 3. Other ABS strategies
• Use of selective reporting of antibiograms (adapted according to local guidelines)
• Electronically available guidelines and/or assisted decision analysis (adapted to or representing 
locally consented practice guidelines) via personal computer, PDA or smartphone
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Table 8  ABS process indicators
TEE transesophageal echocardiograph
a HACEK organisms are a group of Gram-negative pathogens that share an enhanced capacity to produce endocardial infections: Haemophilus 
species (H. parainfluenzae, H. aphrophilus, H. paraphrophilus), Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella 
corrodens, and Kingella species
Community-acquired pneumonia
• Initial therapy (drugs, dosing) according to local/national guideline
• Two sets of blood cultures obtained on the day of therapy initiation
• Monotherapy until day 4 (patients on general wards only)
• Therapy duration no longer than 7 days (patients on general wards only)
Health care-associated pneumonia
• Initial therapy (drugs) according to local/national guideline
• Two sets of blood cultures obtained on the day of therapy initiation
• Therapy duration no longer than 10 days
Bloodstream infection
• Transesophageal echocardiography (TEE) within 10 days after first positive blood culture 
(bloodstream infection due to Staphylococcus aureus, streptococci, [not nosocomial] enterococci, 
HACEKa organisms)
• Follow-up blood cultures on day 4−7 after initial blood culture positivity (bloodstream infection 
due to Staphylococcus aureus and fungi)
Urinary tract infection
• Documented positive urine culture (significant bacteriuria, no mixed flora)
• Initial therapy (drugs; dosing) according to local/national guideline
• Therapy duration no longer than 10 days (pyelonephritis, patients on general wards only)
• Switch to oral administration until day 5 (pyelonephritis, patients on gener wards only)
• No antibiotic therapy for asymptomatic catheter-associated bacteriuria
Parenteral-to-oral switch therapy
• Oral administration of substances with high oral bioavailability (fluoroquinolones [without 
norfloxacin], clindamycin, doxycycline, linezolid, metronidazole, rifampicin, fluconazole, 
voriconazole) (patients without disorders of gastrointestinal resorption, short bowel syndrome,
emesis, severe sepsis/septic shock)
Empiric therapy for indications other than pneumonia and urinary tract infection
• Initial empiric (before/without identified microorganism) therapy (agents) according to local
guideline
Dosing
• Dose adaptation according to renal function within 2 days
Perioperative antibiotic prophylaxis
• Prophylaxis (drugs and dosing) according to local guideline
• Timing: prophylaxis initiation within 1 h before incision
• Timing: prophylaxis discontinued within 1 day
Management of multidrug-resistant microorganisms (MDR)
• Infection and/or colonization by MDR microorganisms explicitly listed in discharge summary
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